Official Title:    A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy  
and Safety Study of Ruxolitinib Cream Followed by a Long-Term  Safety 
Extension Period in Children (Ages ≥ 2 Years to < 12 Years)  With Atopic 
Dermatitis
Study ID: [REMOVED]  
Document Date:  Protocol Amendment 6: 23-February-2023
Incyte Corporation  Page 1 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993 CONFIDENTIAL  Clinical Study Protocol  
TITLE PAGE  
INCB [ZIP_CODE] -305 
Topi[INVESTIGATOR_393556] 3 
(TRuE -AD3)  
A Phase 3, Double -Blind, Randomized, Vehicle -Controlled, Efficacy 
and Safety Study of Ruxolitinib Cream Followed by a Long -Term 
Safety Extension Period in Children (Ages ≥  2 Years to <  12 Years) 
With Atopic Dermatitis
Product:  Ruxolitinib Cream  
IND Number:   
EudraCT number:  2021‐000489‐14  
Phase of Study : 3 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, Delaware, [LOCATION_003]  [ZIP_CODE]  
Original  Protocol:  25 MAR  2021  
Protocol Amendment 1 : 06 MAY 2021  
Protocol Amendment 2:  02 AUG  2021  
Protocol Amendment 3:  19 AUG  2021  
Protocol Amendment 4:  06 APR  2022  
Protocol Amendment 5:  29 JUL 2022  
Protocol Amendment 6:  [ADDRESS_1091309] their origin in the Declaration of 
Helsinki (Brazil 2013) and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and 
applicable laws and country -specific regulations, including WMO (Medical Research Involving Human Participants 
Act) and Clinical Trials Regulation (EU) No. 536/2014, in which the study is being conducted.  
The information in this document is confidential.  No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written consent.  

Incyte Corporation  Page 2 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL    INVESTIGATO R'S AGREEMENT   
I have read the INCB [ZIP_CODE] -305 Protocol  (Amendment 6 dated 22 FEB 2023 ) and agree to  
conduct the study as outlined .  I agree to maintain the confidentiality of all information received 
or developed in connection with this Protocol . 
 
 
   
(Printed Name [CONTACT_7919])    
   
   
(Signature [CONTACT_7919])   (Date)  
Incyte Corporation  Page 3 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
INVESTIGATOR'S AGREE MENT  ................................ ................................ ................................ [ADDRESS_1091310] OF ABBREVIATION S ................................ ................................ ................................ .......... 9 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 11 
2. INTRODUCTION  ................................ ................................ ................................ ......21 
2.1. Background  ................................ ................................ ................................ ................. 21 
2.2. Pi[INVESTIGATOR_9205] 3 Studies and Pi[INVESTIGATOR_791478]  ................................ ...................... 22 
2.2.1.  INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304:  Phase 3 Adolescent/Adult Studies  ........... 22 
[IP_ADDRESS].  Safety  ................................ ................................ ................................ .......................... 22 
[IP_ADDRESS].  Efficacy  ................................ ................................ ................................ ....................... 23 
2.2.2.  INCB [ZIP_CODE] -102:  Pharmacokinetic Pediatric Study  ................................ ................. 25 
[IP_ADDRESS].  Pharmacology Results  ................................ ................................ ................................ 26 
 28 
2.3. Study Rationale  ................................ ................................ ................................ ........... 29 
2.3.1.  Scientific Rationale for Study Design  ................................ ................................ ........ 29 
2.3.2.  Justification for the Selected Treatment Regimen  ................................ ...................... 30 
2.4. Benefit/Risk Assessment  ................................ ................................ ............................ 30 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 32 
4. STUDY DESIGN  ................................ ................................ ................................ .......34 
4.1. Overall  Design  ................................ ................................ ................................ ............ 34 
4.2. Overall Study Duration  ................................ ................................ ............................... 35 
4.3. Study Termination  ................................ ................................ ................................ ......36 
5. STUDY POPULATION  ................................ ................................ ............................. 36 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 36 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......37 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 39 
5.4. Screen Failures  ................................ ................................ ................................ ............ 39 
5.5. Replacement of Participants  ................................ ................................ ....................... 39 
6. STUDY TREATMENTS ................................ ................................ ............................ 40 
6.1. Study Treatments Administered  ................................ ................................ ................. 40 

Incyte Corporation  Page 4 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  6.1.1.  Study Treatment Application Guidance  ................................ ................................ .....41 
6.2. Preparation, Handling, and Accountability  ................................ ................................ 42 
6.3. Measures to Minimize Bias:  Randomization and Blinding  ................................ .......[ADDRESS_1091311] to Follow -Up................................ ................................ ................................ .......49 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 50 
8.1. Administrative and General Procedures  ................................ ................................ .....50 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 50 
8.1.2.  Screening Procedures  ................................ ................................ ................................ ..51 
8.1.3.  Interactive Response Technology Procedure  ................................ .............................. 51 
8.1.4.  Distribution of Reminder Cards and Diaries  ................................ .............................. 52 
8.1.5.  Demography and Medical History  ................................ ................................ .............. 52 
[IP_ADDRESS].  Demographics and General Medical History  ................................ ............................. 52 
[IP_ADDRESS].  Medical and Treatment History  ................................ ................................ .................. 52 
8.2. Efficacy Assessments  ................................ ................................ ................................ .53 
8.2.1.  Health Economics  ................................ ................................ ................................ .......53 
8.2.2.  Body Surface Area  ................................ ................................ ................................ ......53 
Incyte Corporation  Page 5 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  8.2.3.  Target Lesion Identification  ................................ ................................ ....................... 53 
8.2.4.  Photography  ................................ ................................ ................................ ................ 54 
8.2.5.  Investigator's Global Assessment  ................................ ................................ ............... 54 
8.2.6.  Eczema Area and Severity Index  ................................ ................................ ................ 54 
8.2.7.  Itch Numerical Rating Scale  ................................ ................................ ....................... 55 
 55 
8.3. Patient -Reported Outcome Assessments  ................................ ................................ ....56 
 56 
 56 
  
57 
 58 
 58 
 58 
8.4. Safety Assessments  ................................ ................................ ................................ .....58 
8.4.1. Adverse Events  ................................ ................................ ................................ ........... 59 
8.4.2.  Physical Examinations  ................................ ................................ ................................ 59 
[IP_ADDRESS].  Comprehensive Physical Examination  ................................ ................................ .......59 
[IP_ADDRESS].  Targeted Physical Examination  ................................ ................................ .................. 59 
8.4.3.  Vital Signs, Height, and Weight  ................................ ................................ ................. 60 
8.4.4.  Laboratory Assessments  ................................ ................................ ............................. 60 
 61 
[IP_ADDRESS].  Pregnancy Testing  ................................ ................................ ................................ ......61 
[IP_ADDRESS].  Serology  ................................ ................................ ................................ ...................... 61 
 62 
 62 
 62 
8.7. Unscheduled Visits  ................................ ................................ ................................ .....62 
8.8. End of Treatment and/or Early Termination  ................................ .............................. 63 
8.9. Follow -Up ................................ ................................ ................................ ................... 63 
8.9.1.  Safety Follow -Up ................................ ................................ ................................ ........ 63 
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  ...................... 64 

Incyte Corporation  Page 6 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  9.1. Definition of Adverse Event  ................................ ................................ ....................... 64 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 65 
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse Events  ......... [ADDRESS_1091312] OF TABLES  
Table  1: Primary and Key Secondary Objectives and Endpoints  ................................ ............. 11 
Table 2: Key Study Design Elements  ................................ ................................ ....................... 12 
Table  3: Schedule of Activities:  Vehicle -Controlled Period  ................................ ................... 14 
Table  4: Schedule of Activities:  Long -Term Safety Period ................................ ..................... 18 
Table  5: Summary of Treatment -Emergent Adverse Events Occurring in ≥  1% of 
Participants in Any Treatment Group (Phase 3 Atopic Dermatitis 
Vehicle -Controlled P opulation)  ................................ ................................ .................. 23 
Table  6: Study INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304:  Primary and Key 
Secondary Endpoints – Responders at Week 8  ................................ .......................... 24 
Table  7: Objectives and Endpoints  ................................ ................................ ........................... 32 
Table  8: Study Treatment Information  ................................ ................................ ..................... 40 
Table  9: Guidelines for Interruption and Restarting of Treatment Applications if 
Adverse Event Is Deemed Related to the Study Cream  ................................ ............. 45 
Table  10: Investigator's Global Assessment  ................................ ................................ ............... 54 
Table  11: Required Laboratory Analytes  ................................ ................................ .................... 61 
Table  12: Populations for Analysis  ................................ ................................ ............................. [ADDRESS_1091313] OF FIGURES  
Figure 1:  Study Design Schema  ................................ ................................ ................................ .13 
Figure  2: Study INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304:  Proportions of 
Participants Who Achieved IGA -TS ................................ ................................ .......... 24 
Figure  3: Study INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304:  Change F rom 
Baseline in Daily Itch NRS Score  ................................ ................................ .............. 25 
Figure  4: Box Plots of Steady -State Plasma Concentrations Overlaid With Mean 
Values (Log 10 Scale)  ................................ ................................ ................................ ...26 

Incyte Corporation  Page 8 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Figure  5: Study [ZIP_CODE] -102:  P1NP Concentrations for Individual Participants in 
Cohort 6 by [CONTACT_4838]  ................................ ................................ ................................ ........ 27 
  
28 
  
29 
Figure 8:  Study Cream Application Using a Fingertip  ................................ .............................. 41 
Figure  9: Control of the Overall Type I Error Rate  ................................ ................................ ....[ADDRESS_1091314]  aspartate aminotransferase  
BID twice daily  
BSA  body surface area  
  
CFR  Code of Federal Regulations  
COVID -19 coronavirus disease 2019  
CSR  clinical study report  
CTCAE  Common Terminology Criteria for Adverse Events  
  
EASI  Eczema Area and Severity Index  
EASI50/75/90  ≥ 50%/75%/90% improvement in Eczema Area and Severity Index score  
eCRF  electronic case report form  
EDC  electronic data capture  
EOT  end of treatment  
ET early termination  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulation  
GFR  glomerular filtration rate  
HCV  hepatitis C virus  
HIPAA  Health Insurance Portability and Accountability Act of 1996  
HIV human immunodeficiency virus  
IB Investigator 's Brochure  
ICF informed consent form  
ICH International Council for Harmoni sation of Technical Requirements for 
Pharmaceuticals for Human Use  
  
IEC independent ethics committee  
IGA Investigator 's Global Assessment  
IGA-TS Investigator 's Global Assessment Treatment Success  

Incyte Corporation  Page [ADDRESS_1091315](s) or matching 
placebo(s) used for this study.  
Study treatment  This term refers to all medications that the participant is required to  receive 
as part of this study.  
TEAE  treatment -emergent adverse event  
ULN  upper limit of normal  
UV ultraviolet  
  
VC vehicle -control led 

Incyte Corporation  Page 11 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  1. PROTOCOL SUMMARY  
Protocol Title:  
Topi[INVESTIGATOR_791479] 3 (TRuE -AD3)  
A Phase 3, Double -Blind, Randomized, Vehicle -Controlled, Efficacy and Safety Study of 
Ruxolitinib Cream Followed by a Long -Term Safety Extension Period in Children (Ages 
≥ 2 Years to <  12 Years) With Atopic Dermatitis  
Protocol Number:   INCB  [ZIP_CODE] -305 
Objectives and Endpoints : 
Table  1 presents the primary and key secondary objectives and endpoints.  
Table  1: Primary and Key Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To establish the efficacy of ruxolitinib cream in 
participants with AD.  Proportion of participants who achiev e IGA-TS at 
Week  8. 
Key Secondary  
To further assess the treatment effects of 
ruxolitinib cream.  Proportion of participants with a ≥  4-point 
improvement in Itch NRS score from baseline to 
Week  8. 
Proportion of participants with a ≥  4-point 
improvement in Itch NRS score from baseline to 
Day 7  (Week 1) . 
Proportion of participants with a ≥  4-point 
improvement in Itch NRS score from baseline to 
Day 3 . 
Overall Design:  
Table  2 presents the key study design elements.  Further study details are presented after the 
table.  
Incyte Corporation  Page 12 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  2: Key Study Design Elements  
Study  Phase  Phase 3 
Clinical Indication  Atopic dermatitis  
Population  Children age d ≥ 2 years to <  12 years  (with at least 40% of 
participants ages ≥ 2 years to 6 years)  who have been diagnosed 
with AD for at least [ADDRESS_1091316] 
%BSA involvement (excluding the scalp) of 3% to 20%.  
Number of Participants  Approximately 315 participants will be randomized 2:2:1 to 1 of 
3 treatment groups (ruxolitinib cream 0.75% BID [n  = 126], 
ruxolitinib cream 1.5% BID [n  = 126], or vehicle cream BID 
[n = 63]).  The study will be conducted at approximately 60 sites in 
the [LOCATION_002] and Canada.  
Study Design  Randomized (2:2:1), double -blind, VC period (8 weeks) followed by 
[CONTACT_791514] (44 weeks)  and a [ADDRESS_1091317] application of study cream .  In the LTS period, participants 
initially randomized to vehicle cream will be rerandomized (1:1) in a 
blinded manner to ruxolitinib cream 0.75% or 1.5%, and participants 
initially randomized to an active treatmen t group will continue in the 
same treatment group.   
Estimated Duration of Study 
Participation  Screening  period :  up to 28  (+ 7) days 
VC period:  approximately 8 weeks  
LTS period:  approximately 44 weeks  
Safety follow -up period :  [ADDRESS_1091318] study visit  
Total:  up to approximately [ADDRESS_1091319]/Data Monitoring 
Committee  No 
Coordinating Principal 
Investigator  , MD  
Treatment Groups and Duration:  
Male and female c hildren aged ≥ 2 years to <  [ADDRESS_1091320] an IGA score of 2 to 3 and %BSA involvement (excluding the scalp) of 
3% to 20%  will be  eligible to participate in  the study.  Participants who have met all of the 
inclusion  criteria during the screening period (up to 28 days  or up to 35 days for participants 
taking prior medications that require a 4 -week washout period [see Section  5.2, Exclusion 
Criterion 6b ]) will be enrolled (randomized 2:2:1) and receive  blinded  treatment with ruxolitinib 
0.75% cream BID, ruxolitinib 1.5% cream BID, or vehicle cream for a total treatment duration of 
8 weeks during the VC period of the study.  
Participants who complete the Week 8 assessments with no additional safety concerns will 
continue into the 44 -week LTS period with the same treatment regimen, except those initially 
treated with  vehicle  cream will be rerandomized (1:1)  in a blinded manner to 1 of the 2 active 

Incyte Corporation  Page 13 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  treatment groups (ruxolitinib cream 0.75% or 1.5% BID).  The IGA score required for 
participants to enter the LTS period is [ADDRESS_1091321] a %BSA in the range of 
0% to 20% (excluding the scalp).  
Following the end of treatment (Week 52/EOT or ET), all participants will have a safety 
follow -up visit 30 days later (or  [ADDRESS_1091322] application of study treatment  if the 
Week  52/EOT or ET visit was not performed) . 
Figure 1 presents the study design schema, and Table  3 (VC period) and Table  4 (LTS period) 
present the SoA.   Adherence to the study design requirements, including those specified in the 
SoA, is essential and required for study conduct.  
Figure 1: Study Design Schema  
 
 

Incyte Corporation  Page 14 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  3: Schedule of Activities:  Vehicle -Control led Period  
Visit Day (Range)  Screening  VC Period  
Notes and Protocol Section  Days −28 
(+ 7a) to −1  Day 1/  
Baseline  Wk 2  
(± 3 d)  Wk 4  
(± 3 d)  Wk 8b/ET 
(± 3 d)  
Administrative p rocedures  
Informed consent/assent  X     Section  8.1.[ADDRESS_1091323] IRT  X X X X X Section  8.1.3 . 
Inclusion/exclusion criteria  X X    Section  5. 
Demograph y and general medical 
history  X*     Section  [IP_ADDRESS] . 
*Height and weight of both parents, if available, should be obtained and 
entered into the EDC . 
Relevant AD medical and 
treatment history  X     Section  [IP_ADDRESS] . 
Collect/obtain growth 
measurements  for the year prior to 
study entry  X* X*    Section  8.4.3 . 
*Collected at either screening or baseline .  A reasonable effort must be 
made to collect and document measurements prior to baseline.  If unable 
to obtain, the reason should be documented.  
Prior/concomitant medications and 
procedures  X X X X X Section  6.6. 
Apply study cream  at site   X X X X* Section  6.1; at each visit  (except for the Week 8  visit if IGA is 0 ), 
starting at Day 1, the participant should apply the first (morning) 
application under direct site staff supervision  to all areas identified at 
Day 1, even if the AD lesion is cleared or disappeared . 
*Not applicable to the ET visit.  
Weigh and dispense study cream ; 
dispense diary cards   X X X X* Section  6.1 and Section  8.1.4 . 
* Not applicable to the Week 8 visit if IGA score = [ADDRESS_1091324] and weigh study cream ; 
collect diary cards    X X X Section  6.1. 
Assess compliance    X X X Section  6.4. 
Safety a ssessments  
AE assessment  X X X X X Section  8.4.1 . 
Comprehensive physical 
examination  X    X* Section  [IP_ADDRESS] . 
*For the ET visit only.  
Incyte Corporation  Page 15 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  3: Schedule of Activities:  Vehicle -Control led Period  (Continued)  
Visit Day (Range)  Screening  VC Period  
Notes and Protocol Section  Days −28 
(+ 7a) to −1  Day 1/  
Baseline  Wk 2  
(± 3 d)  Wk 4  
(± 3 d)  Wk 8b/ET 
(± 3 d)  
Safety a ssessments  (continued)  
Targeted physical examination*   X X X X† Section  [IP_ADDRESS] .  
*Conducted only when indicated by [CONTACT_791515] 
(ie, AEs or other findings ); clinically sig nificant abnormalities (in the 
investigator 's judgment) are to be reported as AEs.  
†Not done for the ET visit.  
Height and weight   X   X Section  8.4.3 ; height should be measured with a  stadiometer . 
Vital signs  X X X X X Section  8.4.3 ; vital signs are taken before blood sampling and other 
procedures.  
Efficacy a ssessments  
Evaluate %BSA  affected by [CONTACT_22802] 
(excluding skin dryness)  X X X X X* Section  8.2.2 ; evaluate %BSA (excluding the scalp) affected by [CONTACT_791516].  
*At Week 8, the %BSA range is 0% to ≤ 20% for the LTS period .  
Target lesion identification  X X*    Section  8.2.3 ; the longest diameter and the span perpendicular to the 
longest diameter will be measured in centimeters.  
*For photography participants, a  lesion of ≥  5 cm2 (target lesion) is to be 
identified at  screening and  confirmed at the baseline visit (excluding t he 
hands, feet, and genitalia).  
Photography (target lesion and 
regional body area)*   X X X X Section  8.2.4 ; photography of the target lesion area identified at 
Day 1/baseline even if the lesion has cleared . 
*Performed only  for photography participants  at selected sites.  
IGA X X X X X* Section  8.2.5 . 
*At Week 8, the IGA range is 0 to 4 for the LTS period.  
EASI  X X X X X Section  8.2.6 ; evaluate EASI in 4 regions (head/neck, upper limbs, 
trunk, and lower limbs) and overall.  
Itch NRS  eDiary is completed each evening from screening through 
the last application of study cream  during  the VC period 
(night prior to Week 8 visit).  Section  8.2.7 ; baseline itch (defined as the average of at least 4 of the 
7 days directly  before Day 1) must be NRS ≥ 4 . 
Note:  I tch is collected from participants ≥  6 years of age.  

Incyte Corporation  Page 16 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  3: Schedule of Activities:  Vehicle -Control led Period  (Continued)  
Visit Day (Range)  Screening  VC Period  
Notes and Protocol Section  Days −28 
(+ 7a) to −1  Day 1/  
Baseline  Wk 2  
(± 3 d)  Wk 4  
(± 3 d)  Wk 8b/ET 
(± 3 d)  
Laboratory a ssessments  Blood draws for clinical laboratory tests must be performed before the 
in-clinic study cream  application.  
Use of a t opi[INVESTIGATOR_791480] . 
Serum chemistries  X X* X  X Section  8.4.4 . 
*Day 1 testing will be performed  only if the interval between this visit 
and the screening visit is > 2 weeks.  
Hematology  X X* X  X Section  8.4.4 . 
*Day 1 testing will be performed only if the interval between this visit 
and the screening visit is > 2 weeks.  
Serology  X*     Section  [IP_ADDRESS] .  
*HIV antibody.  
Pregnancy testing  X X*   X Section  [IP_ADDRESS] ; at the indicated visits, only female participants who 
have reached menarche will undergo a  urine pregnancy test.  A positive 
urine test mus t be confirmed by a serum test.  
*Day 1 testing will be performed only if the interval between this visit 
and screening is >  2 weeks . 

Incyte Corporation  Page 17 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  3: Schedule of Activities:  Vehicle -Control led Period  (Continued)  
Visit Day (Range)  Screening  VC Period  
Notes and Protocol Section  Days −28 
(+ 7a) to −1  Day 1/  
Baseline  Wk 2  
(± 3 d)  Wk 4  
(± 3 d)  Wk 8b/ET 
(± 3 d)  
Note:  Unscheduled visits may occur at any time at the investigator 's discretion, and appropriate clinical and la boratory tests may be performed  as clinically indicated.  
a For prior medications that require a 4 -week washout period (see Section  5.2, Exclusio n Criterion 6b), a 35 -day screening period is allowed.  
b Week 8 is the baseline for participants eligible to continue in the LTS period (IGA score = 0 -4 and BSA = 0% -20%).  

Incyte Corporation  Page 18 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  4: Schedule of Activities:  Long -Term Safety Period  
Visit Day (Range)  LTS Period  
Unscheduled 
Visit  Safety Follow -Up 
Notes and Protocol Section  Wk 12  
(± 7 d)  Wk 16, 
20, and 24  
(± 7 d)  Wk 28, 
32, and 36  
(± 7 d)  Wk 40, 
44, and 48  
(± 7 d) Wk 52/ 
EOT/ET  
(± 7 d)  30 (+ 7)  Days After 
Last Study Cream  
Applicationa 
Administrative procedures  
Contact [CONTACT_12067]  X X X X X X X Section  8.1.3 . 
Prior/concomitant 
medications and procedures  X X X X X X X Section  6.6. 
Apply study cream  at site  X X X X    Section  6.1; only for participants with active 
AD lesions at time of visit;  apply the first 
(morning ) application under direct site staff 
supervision.  
Weigh and dispense study 
cream ; dispense diary cards  X X X X    Section  6.[ADDRESS_1091325] and weigh study 
cream ; collect diary cards  X X X X X   Section  6.1. 
Record start and end dates 
of treatment cycle(s)  X X X X X   Section  6.1; the start/end date will have been  
recorded  by [CONTACT_2299].  The end date 
should be 3  days after lesions clear ; however,  
if this 3 -day window is during a study visit 
and IGA  score = 0, stop treatment and record 
the date of the study visit as the treatment 
cycle end date.  
Assess c ompliance  X X X X X   Section  6.4. 
Safety assessments  
AE assessments  X X X X X X X Section  8.4.1 . 
Comprehensive physical 
examination      X   Section  [IP_ADDRESS] . 
Targeted physical 
examination  X X X X  X X Section  [IP_ADDRESS] ; conducted only when 
indicated by [CONTACT_791517] (AEs or other findings); clinically 
significant abnormalities (in the investigator's 
judgment) are to be reported as AEs.  
Incyte Corporation  Page 19 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  4: Schedule of Activities:  Long -Term Safety Period  (Continued)  
Visit Day (Range)  LTS Period  
Unscheduled 
Visit  Safety Follow -Up 
Notes and Protocol Section  Wk 12  
(± 7 d)  Wk 16, 
20, and 24  
(± 7 d)  Wk 28, 
32, and 36  
(± 7 d)  Wk 40, 
44, and 48  
(± 7 d)  Wk 52/ 
EOT/ET  
(± 7 d)  30 (+ 7)  Days After 
Last Study Cream  
Applicationa 
Safety assessments (continued)  
Height and weight   X*   X   Section  8.4.3 ; height should be measured 
with a stadiometer . 
*Only at Week 24.  
Vital signs  X X X X X X X Section  8.4.3 ; vital signs are taken before 
blood sampling and other procedures.  
Disease severity assessments  
Evaluate %BSA  affected by 
[CONTACT_791518]  X X X X X X X Section  8.2.2 ; evaluate %BSA (excluding the 
scalp) affected by [CONTACT_791519].  
IGA X X X X X X X Section  8.2.5 . 

Incyte Corporation  Page 20 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  4: Schedule of Activities:  Long -Term Safety Period  (Continued)  
Visit Day (Range)  LTS Period  
Unscheduled 
Visit  Safety Follow -Up 
Notes and Protocol Section  Wk 12  
(± 7 d)  Wk 16, 
20, and 24  
(± 7 d)  Wk 28, 
32, and 36  
(± 7 d)  Wk 40, 
44, and 48  
(± 7 d)  Wk 52/ 
EOT/ET  
(± 7 d)  30 (+ 7)  Days After 
Last Study Cream  
Applicationa 
Laboratory assessments  Blood draws for clinical laboratory tests must 
be performed before the in -clinic study 
cream  application.  
Serum chemistries  X X* X* X* X X X Section  8.4.4 . 
*Only at Weeks 16, 24, 32, 40, and 48.  
Hematology  X X* X* X* X X X Section  8.4.4 . 
*Only at Weeks 16, 24, 32, 40, and 48.  
Pregnancy testing   X* X* X*   X Section  [IP_ADDRESS] ; at the indicated visits, only 
female participants who have reached 
menarche will have urine pregnancy test.  A 
positive urine test must be confirmed by a 
serum test.  
*Only at Weeks 16, 24, 32, 40, and 48.  
Note:  Unscheduled visits may occur at any time at the investigator 's discretion, and appropriate clinical and la boratory tests may be performed  as clinically indicated.  
a Except for participants who have been in an observation/no treatment cycle with a total IGA s core of 0 (clear) from Week 48 or earlier until Week 52; such participants should 
complete the safety follow -up and Week 52/EOT visits together. In practice, this would mean conducting all Week 52/EOT visit assessments plus the pregna ncy test at the 
Week  52/EOT visit.  

Incyte Corporation  Page 21 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  2. INTRODUCTION  
2.1. Background  
Ruxolitinib cream is a topi[INVESTIGATOR_791481].  Ruxolitinib phosphate is an inhibitor of the JAK family of protein tyrosine 
kinases.  Inflammatory cytokines are strongly implicated in the pathogenesis of several 
dermato logic diseases.  Because JAKs serve to translate extracellular signals from a number of 
relevant cytokines and growth factors upregulated in inflammatory diseases such as AD, alopecia 
areata, plaque psoriasis, and vitiligo, JAK inhibitors represent potenti al therapeutic agents for 
these disease states ( Howell  et al 2019 ). 
Atopic dermatitis is a chronic, recurring, inflammatory, and highly pruritic skin condition that 
affects up to 25% of children and up to 12% of adults worldwide ( Eichenfield et al 2014 , Hanifin 
et al 2007 , Harrop et al 2007 , Rönmark et al 2012 , Vinding et al 2014 ) and is one of the most 
common dermatoses encountered by [CONTACT_501014] .  Although not 
life-threatening, patients with AD are at a higher risk for the development of other potentially 
life-threatening disorders  such as asthma and/or food allergy ( Spergel  2010 ).  According to the 
recent Global Burden of Disease project, AD is one of the [ADDRESS_1091326] disability ranking of all nonmal ignant skin diseases ( Hay et al 2014 ). 
The clinical pattern of AD varies with age and generally develops during the first 5 years of life 
in 90% of patients (but not in the first weeks of life, as seen in the autosomal dominant 
hyper -immunoglobulin E syndrome ; Lyons  et al 2015 ).  Infants usually show acute erythematous 
and often exudative papules on the face or scalp, which are often intensely pruritic.  The 
childhood phase (2 years of age to puberty) and adult phase of AD tend to have less acute or 
exudative lesions but instead typi[INVESTIGATOR_393571] 
(flexural folds, the face and neck, the upper arms and back, and the dorsa of the hands, feet, 
fingers, an d toes), which represent a more chronic stage of the condition ( Akdis  et al 2006 ).  The 
unifying and cardinal feature of all presentations of AD is the pronounced and often unbearable 
itching.  
In addition to the allergy -related sequelae of AD affecting the skin, recent reports have shown 
that children with AD, compared to those without AD, are at a higher risk of developi[INVESTIGATOR_791482] -deficit/hyperactivity disorder and depression 
(de la O-Escamilla and  Sidbury  2020 , Hong  et al 2019 , van der Schans  et al 2017 , 
Yaghmai e et al 2013 ).  Sleep disturbance, both in pediatric patients and their parents/caregivers, 
is also common and can significantly impair quality of life ( Chang  and Chiang 2018 , 
Ramire z et al 2019 , Yang  et al 2019 ). 
Despi[INVESTIGATOR_249669] a number of treatment options, there is still a significant medical need 
for safe topi[INVESTIGATOR_791483], particularly in children .  Moderate to potent topi[INVESTIGATOR_791484] -known safety restrictions limiting their use to 
4 and 8 weeks, respectively.  In addition, a P DE4 inhibitor, 2% crisaborole (Eucrisa®) ointment, 
was recently approved in the [LOCATION_002]  for patients aged [ADDRESS_1091327]  efficacy  
(Eucrisa  2020 ). 
For patients with more severe AD, the most recent addition to the systemic drug armamentarium 
is dupi[INVESTIGATOR_12458] ( Dupi[INVESTIGATOR_12460]® 2020 ).  Dupi[INVESTIGATOR_24783] a monoclonal humanized antibody against 
IL-4Rα that blocks the act ion of IL -[ADDRESS_1091328] recently in children age d 6 years and older in the 
[LOCATION_002]  (Dupi[INVESTIGATOR_12460] 2020 ). 
Studies with oral JAK inhibitors (tof acitinib and baricitinib) indicated that these drugs may be 
effective in the treatment of patients with AD ( Levy  et al 2015 , Napolitano  et al 2020 ) and have 
triggered further intere st in their use as topi[INVESTIGATOR_393563].  A clinical study 
with topi[INVESTIGATOR_791485] ( Bissonnette  et al 2016 ).  Consequently, efforts have been made to find new treatment 
possibilities that would more appropriately address the m edical needs of patients with AD. 
Janus kinases  are intracellular signaling enzymes that act downstream of key proinflammatory 
cytokines known to promote the pathogenesis  of AD .  Ruxolitinib (INCB018424) is a potent and 
selective JAK1 and JAK2 inhibitor that is currently approved for use in tablet form for the  
treatment of patients with  myelofibrosis and polycythemia vera in multiple countries and acute 
graft-versus -host disease in the [LOCATION_002] .  Recent studies suggest that JAK inhibition may 
have antipruritic effects by [CONTACT_791520] a novel 
therapeutic approach with dual anti -inflammatory and antipruritic proper ties. 
Nonclinical pharmacology, PK/PD, and toxicology data for ruxolitinib cream from in vitro and 
in vivo model systems support the use of topi[INVESTIGATOR_791486], psoriasis, vitiligo, and other inflammato ry diseases of the skin.  Refer to the 
ruxolitinib cream IB  for a summary of findings from the nonclinical studies.  
2.2. Pi[INVESTIGATOR_9205] 3 Studies and Pi[INVESTIGATOR_791478]  
2.2.1.  INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304:  Phase 3 Adolescent/A dult Studies  
The ruxolitinib cream Phase 3 studies (INCB [ZIP_CODE] -303 and  INCB  [ZIP_CODE] -304) confirmed that 
1.5% ruxolitinib cream applied BID for 8 weeks is a highly effective treatment for participants  
with AD and is not associated with safety concerns.  A lower strength of ruxolitinib cream 
(0.75% BID for 8 weeks) was also investigated in these trials.  While its safety profile was not 
different from that of 1.5% cream, it was less efficacious than the highe r strength.  
[IP_ADDRESS].  Safety  
The primary analysis of the safety of ruxolitinib cream is based on pooled data from the VC 
period of the 2 confirmatory Phase 3 studies, INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304 (ie, the 
Phase 3 AD VC  population), in 1249 adolescents and adult s with AD.  Participants were 
randomized 2:2:1 to ruxolitinib 0.75% cream BID (500 participants), ruxolitinib 1.5% cream 
BID (499 participants) , or vehicle cream BID (250 participants).  
The most frequently reported TEAEs during the VC period are summarized  in Table  5 and were 
consistent with the types of events that are common in patients with AD.  The overall rate of 
Incyte Corporation  Page 23 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  TEAEs in both studies after 8 weeks of treatment was comparable between the ruxolitinib cream 
regimens (0.75% BID, 29.0%; 1.5% BID, 26.5%) and vehicle cream (33.2%).  
Table  5: Summary of Treatment -Emergent Adverse Events Occurring in ≥  1% of 
Participants in  Any Treatment Group (Phase 3 Atopic Dermatitis 
Vehicle -Controlled Population)  
MedDRA Preferred Term, n (%)  Vehicle Cream 
BID 
(N = 250)  Ruxolitinib Cream Regimen  Ruxolitinib 
Cream Total  
(N = 999)  0.75% BID  
(N = 500)  1.5% BID  
(N = 499)  
Participants with any TEAE  83 (33.2)  145 (29.0)  132 (26.5)  277 (27.7)  
Nasopharyngitis  2 (0.8)  15 (3.0)  13 (2.6)  28 (2.8)  
Upper respi[INVESTIGATOR_1092]  5 (2.0)  7 (1.4)  12 (2.4)  19 (1.9)  
Headache  5 (2.0)  4 (0.8)  11 (2.2)  15 (1.5)  
Oropharyngeal pain  3 (1.2)  3 (0.6)  5 (1.0)  8 (0.8)  
Application site paina 12 (4.8)  3 (0.6)  4 (0.8)  7 (0.7)  
Application site pruritus  7 (2.8)  5 (1.0)  1 (0.2)  6 (0.6)  
Pruritus  4 (1.6)  2 (0.4)  4 (0.8)  6 (0.6)  
Dermatitis atopi[INVESTIGATOR_449677] 11 (4.4)  1 (0.2)  2 (0.4)  3 (0.3)  
a  Event lowest level terms included application site burning, application site stinging, and pain after application . 
b Reported terms of atopic dermatitis flare, atopic dermatitis exacerbation, exacerbation of atopic dermatitis, intensification  of 
atopic dermatitis, worsening of atopic dermatitis, flare of atop ic dermatitis . 
The frequency of application site reactions was low (1.6% and 1.0% in participants who applied 
ruxolitinib 0.75% and 1.5% cream BID, respectively, and 7.6% in participants who applied 
vehicle cream BID); no clinically significant application  site reactions were observed, including 
areas of sensitive skin (eg , the face).  The rate of SAEs  was comparable among  all treatment 
groups (0.75% ruxolitinib BID, 0.8%; 1.5% ruxolitinib BID, 0.6%; vehicle cream BID, 0.8%).  
Long-term safety data (44 -week  extension period of both studies) did not identify any safety 
concerns with prolonged intermittent use of ruxolitinib cream.  
[IP_ADDRESS].  Efficacy  
In Study INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304, s ignificantly more participants  achieved 
IGA-TS with application of ruxolitinib cream  0.75% BID (50.0% and 39.0%) and 1.5% BID 
(53.8% and 51.3%) versus  vehicle cream (15.1% and 7.6%; all p < 0.0001; see Figure  2), 
respecti vely. 
Incyte Corporation  Page 24 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Figure  2: Study INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304:  Proportion s of 
Participants Who Achieved  IGA -TS 
INCB [ZIP_CODE] -303         INCB [ZIP_CODE] -304 
 
In Study  INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304, EASI75 was achieved by 56.0% and 
51.5% of participants  applying ruxolitinib cream 0.75% BID, 62.1% and 61.8% of participants 
applying ruxolitinib cream  1.5% BID, and  24.6% and 14.4% of participants applying  vehicle 
cream (all p < 0.0 001), r espectively.   A summary of the primary and select key secondary 
endpoints of resp onders at Week  8 is shown in Table  6. 
Table  6: Study INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304:  Primary and Key 
Secondary Endpoints – Responders at Week 8  
 INCB [ZIP_CODE] -303 INCB [ZIP_CODE] -304 
Vehicle 
Cream 
BID 
(N = 126)  Ruxolitinib 
0.75% 
Cream BID  
(N = 252)  Ruxolitinib 
1.5% 
Cream BID  
(N = 253)  Vehicle 
Cream 
BID 
(N = 118)  Ruxolitinib 
0.75% 
Cream BID  
(N = 231)  Ruxolitinib 
1.5% 
Cream BID  
(N = 228)  
IGA-TSa 15.1% 50.0%b 53.8%b 7.6% 39.0%b 51.3%b 
EASI75c 24.6%  56.0%b 62.1%b 14.4%  51.5%b 61.8%b 
Itch NRS (≥ 4 -point 
reduction)d 15.4%  40.4%e 52.2%b 16.3%  42.7%b 50.7%b 
a IGA-TS was defined as an IGA score of 0 or 1 with a ≥ 2 -grade improve ment from baseline.  
b p < 0.0001, ruxolitinib cream versus vehicle.  
c An EASI75 responder was defined as a participant achieving ≥ 75%  improvement from baseline in EASI score.  
d An Itch 4 NRS responder was defined as a participant achieving a ≥ 4 -point improvement from baseline in Itch NRS score.  
The denominator includes participants in the ITT population with baseline Itch NRS score ≥ 4.  
e p < 0.001, ruxolitinib cream versus vehicle cream.  
In both studies, significantly greater itch reduction was observed within [ADDRESS_1091329] 
application of ruxolitinib cream 1.5% BID versus  vehicle  cream  (p < 0.05; see Figure  3).  At 
Week 8, clinically meaningful reduction ( ≥ 4-point improvement in I tch NRS  score ) was 
achieved by [CONTACT_791521] (0.75% BID, 40.4% and 42.7%; 
1.5% BID, 52.2% and 50.7%) versus  vehicle cream (15.4% and 16.3%, respectively; all 
p < 0.0001). 

Incyte Corporation  Page 25 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Figure  3: Study INCB [ZIP_CODE] -303 and Study INCB [ZIP_CODE] -304:  Change From Baseline 
in Daily Itch NRS Score  
INCB [ZIP_CODE] -303         INCB [ZIP_CODE] -304 
 
Overall, ruxolitinib cream demonstrated superior efficacy versus  vehicle cream for endpoints 
including IGA -TS, EASI75 , and ≥ 4-point improvement in Itch NRS  score .  The safety profile 
was similar to that of vehicle cream and consistent between the 2 studies , and the rate of 
application site reactions was low.  
2.2.2.  INCB [ZIP_CODE] -102:  Pharmacokinetic Pediatric Study  
The pi[INVESTIGATOR_791487] (INCB [ZIP_CODE] -102), an open -label, de scending age (≥  12 to 17  years, 
≥ 7 to < 12 years, and ≥  2 to <  7 years) , and increasing treatment strength (0.5%, 0.75%, or 
1.5%) trial, was conducted to explore primarily the safety of several treatment regimens with 
ruxolitinib cream.  Although not a do se range –finding study, it showed  that the efficacy and 
safety of ruxolitinib cream 0.75% and 1.5% BID were similar in this pediatric age population to 
that in adolescents and adults with AD.  
The results of Study INCB  [ZIP_CODE] -102 indicate that ruxolitinib cr eam at the 0.5%, 0.75%, and 
1.5% strengths was safe and well -tolerated when administered BID for 4 weeks to pediatric 
participants with AD (aged ≥ 2 to 17 years).  A summary of the results is listed below:  
• There were no serious TEAEs or TEAEs with a fatal outcome.  One participant 
(7.1%) in Cohort 6 (≥  2 to <  7 years; ruxolitinib 1.5% cream BID) had a 
treatment -related TEAE of decreased neutrophil count with onset on Day 9 that led to 
study cream  discontinuation.  The event was Grade  1 in severity and resol ved after 
49 days.  
• The overall incidences of TEAEs were highest among participants ≥ 12 to 17 year s 
old (50.0% and 45.5% for Cohorts 1 and 2, respectively) and did not vary according 
to ruxolitinib cream strength.  Treatment -emergent AEs were Grade 1 or 2 in severity 
with the exception of 2  Grade 3 events, tooth fracture and lip injury, in a participant 
in Cohort 3 (≥  7 to < 12 years; ruxolitinib 0.75% cream BID).  

Incyte Corporation  Page 26 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • The most frequently reported TEAEs overall were headache (5.6%), atopic dermatitis 
(reported a s worsening, flares, or exacerbations of atopic dermatitis; 4.2%), and otitis 
media and upper respi[INVESTIGATOR_1092] (2.8% each).  
• The incidence of application site reaction TEAEs was low:  1  participant (10.0%) in 
Cohort  1 (≥ 12 to 17 years; ruxolitin ib 0.5% cream BID) had an event of application 
site urticaria, and 1  participant (7.1%) in Cohort 4 (≥  7 to <  12 years; ruxolitinib 1.5% 
cream BID) had 2  events of application site pain (reported term:  stinging sensation).  
All application site reaction T EAEs were Grade 1 in severity and resolved on the 
same day as the event onset.  
• There were no clinically meaningful changes in mean chemistry or hematology 
parameters over time, and no clinically meaningful changes were noted for vital signs 
or height.  
[IP_ADDRESS].  Phar macology Results  
Plasma concentrations of ruxolitinib were in general low and showed substantial interindividual 
variability in all cohorts.  The steady -state plasma concentrations of ruxolitinib increased in a 
less than proportional manner as the formulat ion strength increased.  Mean steady -state plasma 
concentrations of ruxolitinib are shown in Figure  4. 
Figure  4: Box Plots of Steady -State Plasma Concentrations Overlaid With Mean 
Values (Log 10 Scale)  
 
Note:  Gray circles represent outliers (> 1.5 × interquartile range ). 

Incyte Corporation  Page 27 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Overall, plasma PK of ruxolitinib in adolescent participants aged ≥ 12 to 17 years who applied 
ruxolitinib cream were similar to those previously observed in adult patients with AD. 
Evaluation of serum bone markers related to bone development was included in the safety 
assessments for Cohorts 3 to 6 to provide safety monitoring for early detection of possible bone 
effects on P1NP and BSAP (bone formation markers) and CTx (a bone resor ption marker).  
A percentage decrease from the pretreatment levels (average of screening and baseline values) 
was used to monitor bone biomarker fluctuations in each participant.  
Bone biomarker values were variable between participants.  The normal ranges o f serum bone 
biomarkers in children typi[INVESTIGATOR_791488].  Spaghetti 
plots of BSAP, CTx , and P1NP serum concentrations were used to illustrate the changes in these 
bone markers.  A spaghetti plot from the younges t age group treated with 1.5% ruxolitinib cream 
(Cohort 6; ≥  2 to <  7 years) is shown in Figure  5.  This was the youngest age group treated with 
the highe st strength of ruxolitinib cream and thus the most vulnerable from a safety point of 
view.  This plot was also representative of the other cohorts in which bone markers were 
evaluated (Cohorts 3 -5). 
Figure  5: Study [ZIP_CODE] -102:  P1NP Concentrations for Individual Participants in 
Cohort [ADDRESS_1091330] of ruxolitinib 
cream on bone growth.  

Incyte Corporation  Page 28 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL    

Incyte Corporation  Page 29 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  2.3. Study Rationale  
Ruxolitinib cream is a potent  inhibitor of JAK1 and JAK2 with dual anti -inflammatory and 
antipruritic properties  and has been recently shown to be an effective and safe  therap y for AD in 
patients ≥ 12 years of age ( Kim et al 2020a , Kim et al 2020b , Papp et al 2020 ).  Given its topi[INVESTIGATOR_676093], treatment of AD with r uxolitinib cream  selectively targets th e diseased skin and 
minimizes the chance of safety concerns associated with the systemic administration of JAK 
inhibitors.  
Five studies have been conducted to date evaluat ing the safety and efficacy of ruxolitinib cream 
in patients with AD (see Section  2.2):  a Phase 1 maximum use trial (INCB [ZIP_CODE] -103), a 
Phase  2 study (INCB [ZIP_CODE] -206), 2 Phase 3 studies (INCB [ZIP_CODE] -303 and -304; TRuE -AD1  and 
TRuE -AD2), and a Phase 1 pediatric PK study (INCB [ZIP_CODE] -102).  The results consistently 
demonstrated that ruxolitinib 1.5% cream is a safe and efficacious treatment of AD in adolescent 
participants  and are in line with similar outcomes in adult part icipants . 
This Phase 3 pediatric trial is a part of the pediatric clinical  program with the objective to  
evaluate the efficacy and safety of ruxolitinib cream  in children  with AD ≥  2 years to <  12 years 
of age . 
2.3.1.  Scientific Rationale for Study Design  
Two identical Phase 3 studies (TRuE AD -1 and TRuE AD -2) were conducted to evaluate the 
efficacy of ruxolitinib cream in adolescents and adults ≥ 12 years of age with AD.  The present 
study is intended to investigate and eventually confirm the findings of t he above studies in a 
pediatric population ≥ 2 years to < 12 years of age.  Owing to the prevalence of AD in patients 
< 12 years of age and the unmet need for novel topi[INVESTIGATOR_791489]/safety 

Incyte Corporation  Page 30 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  ratios in this age group, this study will e valuate the safety and efficacy profile of ruxolit inib 
cream in younger children.  
This Phase 3 pediatric trial  (INCB [ZIP_CODE] -305) is a double -blind study composed of sequential 
VC and LTS periods lasting [ADDRESS_1091331] after stoppi[INVESTIGATOR_791490] (flare) epi[INVESTIGATOR_1841].  
Additionally, this treat/re -treat manner of administration may reflect t he likely use of the product 
in the post -approval, real-world  setting.  Other measures included in this study are  Itch  
,   
 
 
2.3.2.  Justification for the Selected Treatment Regimen  
The ruxolitinib cream Phase 2 dose range –finding study (INCB [ZIP_CODE] -206) in adult participants 
with AD was the basis for the treatment strength selection for the Phase 3 studies.  There were no 
meaningful differences in safety between all treatment regimens , and all treatment arms  
demonstrated unremarkable safety profiles with good tolerability on applicat ion sites . 
The 1.5% BID regimen was found to be the most efficacious , with the near-maximal treatment 
effect obtained within 8 weeks of therapy  and the leveling of response thereafter.  In addition, 
a prompt and pronounced decrease in itch was observed rel ative to the other active treatment 
groups.  Given that the 1.5% strength (BID, for up to 8 weeks) dem onstrated the highest 
efficacy/ safety ratio, this particular regimen was selected for the consecutive clinical studies.  
Although ruxolitinib  0.75% BID was  not tested in the earlier phase 2 dose range –finding study , 
the distinctive dose responses seen allowed the projection of its efficacy level to be intermediate 
between the 0.5% once daily and 1.5% BID strength s.  It was also anticipated that reducing the 
ruxolitinib cream strength would lead to reduced systemic exposure.  
While t he efficacy of 1.5% ruxolitinib cream in the Phase 3 studies in adults and adolescents 
with AD was superior to that of 0.75% ruxolitinib cream, there were no meaningful differences 
in the safety profiles of these 2 regimens.   However, there is a possibility that plasma levels of 
ruxolitinib may be relatively higher, especially in younger children (with a higher BSA/body 
mass ratio), than those observed in adolescent and adult partici pants.  Therefore, both regimens 
will be evaluated in subsequent studies.  
2.4. Benefit/Risk Assessment  
See Appendix  C for COVID -19–related guidance . 
Despi[INVESTIGATOR_791491], there is still a significant medical need for topi[INVESTIGATOR_791492], particularly in chi ldren.  The overall benefit /risk 
assessment of ruxolitinib cream favors its use in adolescent and adult patients with AD, 
including those with involvement of sensitive skin areas (eg, the face).  Ruxolitinib cream 

Incyte Corporation  Page 31 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  rapi[INVESTIGATOR_791493] (erythema, induration/papulation, and oozing/crusting) 
and symptoms, most importantly pruritus, of AD. 
All clinical studies with ruxolitinib cream in AD conducted to date confirm that both the 0.75% 
and 1.5% BID treatment regimens are most efficacious, com pared with lower strengths of 
ruxolitinib cream evaluated, and are not associated with any concerning safety findings.  
Treatment with ruxolitinib cream  1.5% BID for 8 weeks demonstrated better efficacy and similar 
safety to the 0.75% BID treatment regimen , resulting in a better benefit/risk ratio in adolescents 
and adults.  
A pi[INVESTIGATOR_791487] ( INCB [ZIP_CODE] -102) demonstrated a similar risk/benefit ratio for each 
treatment strength in pediatric participants (aged ≥  2 to 17  years, inclusive).  See Section  2.2.2 . 
The Phase 3 pi[INVESTIGATOR_791494] (INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304) in 
adolescent s and adults with AD are ongoing.  However, the preliminary data are in line with the 
findings from other studies in terms of the efficacy and safety of this drug.  See Section  2.2. 
Based on the above information, ruxolitinib cream up to 1.5% BID can be safely used as a 
topi[INVESTIGATOR_393579] /risk ratio 
from among those investigated.  
More deta iled information  about the known and expected benefits and risks and reasonably 
expected AEs of ruxolitinib cream may be found in the ruxolitinib cream IB . 
Incyte Corporation  Page 32 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  3. OBJECTIVES AND ENDPOINTS  
Table  7 presents the objectives and endpoints.  
Table  7: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To establish the efficacy of ruxolitinib cream in 
participants with AD.  Proportion of participants who achiev e IGA-TS at 
Week  8. 
Key Secondary  
To further assess the treatment effects of ruxolitinib 
cream.  • Proportion of participants with a ≥  4-point 
improvement in Itch NRS score from  baseline to 
Week  8.  
• Proportion of participants with a ≥  4-point 
improvement in Itch NRS score from baseline to 
Day 7 (Week 1) . 
• Proportion of participants with a ≥  4-point 
improvement in Itch NRS score from baseline to 
Day 3.  
Secondary  
To evaluate the safety and tolerability of ruxolitinib 
cream.  The type, frequency, and severity of AEs  and changes 
from baseline in physical examinations , vital signs , 
height, weight, and laboratory data for hematology and 
serum chemistry.  
To further evaluate the efficacy of ruxolitinib cream.  • Proportion of participants who achiev e IGA-TS at 
Weeks 2 and 4.  
• Proportion of participants with a ≥ 4 -point 
improvement in Itch NRS score from baseline to 
Weeks 2 and 4.  
• Proportion of participants who achieve EASI75 at 
Weeks 2, 4, and 8. 
• Time to achieve Itch NRS score improvement of at 
least 2 or 4 points.  

Incyte Corporation  Page 33 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  7: Objectives and Endpoints  (Continued)  
Objectives  Endpoints  

Incyte Corporation  Page 34 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  4. STUDY DESIGN  
4.1. Overall Design  
This is a randomized, double -blind, VC study with an LTS  period in pediatric participants with 
AD eligible for topi[INVESTIGATOR_8588] , to be conducted at approximately 60 sites in the [LOCATION_002] 
and Canada.   For participants who meet all study inclusion criter ia and none of the exclusion 
criteria, study cream  will be assign ed at the Day 1/baseline  visit.  Participants will be randomized 
2:2:1 to blinded treatment with ruxolitinib cream 0.75% BID, ruxolitinib cream 1.5% BID, or 
vehicle cream BID,  with stratification by [CONTACT_791522].  Enrollment will be capped 
such that no more than approximately 25%  of randomized participants have a baseline IGA score 
of 2.  At least 40% of the overall study population will consist of children aged ≥  2 years to 
6 years.  
During the 8 -week VC period, participants will apply study treatment BID to all areas identified 
for treatment at the Day 1/baseline visit even if the AD begins to improve and lesions decrease  in 
size.  Note:  Throughout this protocol, the t erm "participant " refers either to the participants 
themselves or, in the case of younger children, their parent or legal guardian . 
At Week 8, efficacy ( the primary endpoint  of the study)  will be evaluated as the proportion of 
participants achieving treatm ent success (IGA score of 0 or 1 with ≥ 2 -grade improvement from 
baseline).  
Participants who complete Week 8 assessments with no additional safety concerns will continue 
into the 44 -week LTS period with the same treatment regimen, except those initially randomized 
to vehicle  cream will be rerandomized (1:1) in a blinded manner to 1 of the 2 active treatment 
groups (ruxolitinib cream 0.75% or 1.5% BID).  The IGA score required for participants to enter 
the LTS period is [ADDRESS_1091332] a % BSA in the range of 0% to 20% 
(excluding the scalp).  
During the LTS period, participants will have study visits every 4 weeks until the end of the 
study (52  weeks total).  At each of these visits, including Week 8 (baseline  visit for the LTS 
period), the p articipant 's AD lesions will be evaluated by [CONTACT_791523] (re)enter an observation/no treatment 
cycle.  If the IGA score is ≥ 1, the participant will start or continue ac tive treatment with 
ruxolitinib cream (0.75% or 1.5%) BID.  If the IGA score is 0 (clear), the participant will 
(re)enter an observation/no treatment cycle.  
During the LTS period (ie, starting at the Week 8 visit), participants will self -evaluate the 
recurrence of AD and will treat areas of the skin with active AD changes only (not to exceed 
20% BSA).  If AD lesions clear between study visits, participants will stop treatment 
applications [ADDRESS_1091333] the dates o f these events in their 
diaries.  Similarly, those participants whose AD lesions recurred and who were previously in an 
observation/no treatment cycle will restart treatment at home at the first sign of recurrence and 
record the date of the new treatment c ycle.  All cycles of treatment will be captured in the study 
database with their beginning and end dates.  
Throughout the study (VC period or LTS period), participants who develop new or expanded 
areas of AD may treat these additional areas with approval by  [CONTACT_791524] 20% and there are no safety concerns regarding the additional 
Incyte Corporation  Page 35 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  application of study cream .  Approval to treat additional areas may occur via telephone, although 
the investigator, at his/her discretion, may ask the participant to return for an unscheduled visit.  
This is a close reflection of the clinical practice of managing AD in the outpatient setting.  
If the participant does not have a response during the LTS period (defined as no 
change/i mprovement in either %BSA or IGA score when treated continuously for 8 weeks 
during the LTS  period ), the participant must  be discontinued from study treatment and an ET 
visit performed.  
Throughout the study, p articipants will be assessed for safety and tolerability by [CONTACT_501019], frequency, and severity of AEs; performing physical examinations; measuring  vital signs , 
height , and weigh t; and conducting clinical  and laboratory assessments as outlined in the SoA 
(see Table  3 [VC period] and Table  4 [LTS period] ).  Additional disease severity assessments, 
including PROs, will be conducted as outlined in the SoA (see Table  3 and Table  4). 
 
 
Following the end of treatment (Week 52/EOT or ET), all participants will have a safety 
follow -up visit [ADDRESS_1091334] been in an observation/no treatment cycle  with an  IGA score 
of 0 (clear)  from  Week 48 or earlier  until Week 52 ; such participant s could complete the safety 
follow -up and Week 52/EOT visit s together .  In practice, this would mean conducting all 
Week  52/EOT visit assessments  plus the pregnancy test at the Week 52/EOT visit . 
Figure 1 presents the study design schema, and Table  3 (VC period) and Table  4 (LTS period) 
present the SoA.  
4.2. Overall Study Duration  
Participants will participate in the  study for a duration of up to approximately 61 weeks : 
28 (+ 7) days in the screening  period , 8 weeks in the VC period, 44 weeks in the LTS period, and 
30 days in the  safety follow -up period  (see Figure 1). 
The study will b egin when the first participant (or parent or guardian) signs the ICF (and , if 
needed, an  assent form).  The end of the study is defined as the date of the last visit of the last 
participant in the study or the date that the last participant has discontinu ed study cream  and has 
completed applicable safety follow -up assessments  or is lost to follow -up. 
A participant is considered to have completed the study if he/she has completed all study visits, 
including the safety follow -up visit.  
The investigator will be expected to monitor for and report any SAEs and pregnancies, as 
detailed in Section  9.  The remaining participants are considered to be on study unt il a 
discontinuation criterion is met and written notification is provided to the sponsor.  

Incyte Corporation  Page [ADDRESS_1091335] .  The inves tigator is to notify the IRB /IEC of the study 's 
completion or early termination  in writing , send a copy of the notification to the sponsor or 
sponsor 's designee, and retain 1  copy for the site study regulatory file.  
The sponsor may terminate the study elec tively or if required by [CONTACT_352931].  In the event 
of significant safety findings, the study will be terminated.  If the study is terminated 
prematurely, the sponsor will notify the investigators, the IRBs and IECs, and regulatory bodies 
of the deci sion and reason for termination of the study.  
5. STUDY POPULATION  
Deviations from eligibility criteria are not allowed because they can potentially jeopardize the 
scientific integrity of the study, regulatory acceptability, and/or participant  safety .  Therefo re, 
adherence to the criteria as specified in the Protocol is essential .  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or 
exemptions, are not permitted.  
5.1. Inclusion Criteria  
Participants a re eligible to be included in the study only if all of the following criteria apply:  
1. Male and female children age d ≥ 2 years to < 12  years  (at the screening  visit). 
2. Diagnosis of  AD as defined by [CONTACT_85811] ( 1980 ) criteria.  
3. AD duration of at least 3 months (participant/parent/guardian may verbally report signs 
and symptoms of AD with onset at least 3 months prior).  
4. IGA score of 2 to 3 at the screening and baseline  visits . 
5. %BSA (excluding the scalp) with AD involveme nt of 3% to 20% at the screening and 
baseline  visits . 
6. For children aged  6 years to < 12 years , baseline  itch NRS score ≥ 4 (see Section  8.2.7 ).  
Note: Participants who are aged 6 years to < [ADDRESS_1091336] 4 of the 7 days  immediately prior to the Day 1/ baseline visit.  
7. Participants/guardians who agree to discontinue all agents used by [CONTACT_791525] -up visit.  
8. For participants who sign photography consent, a t least [ADDRESS_1091337] be representative 
of the participant 's disease state but not located on the hands, feet, or genitalia.  
Incyte Corporation  Page 37 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  9. For sexually active participants, willing ness to take appropriate contraceptive meas ures 
(see Appendix  A) to avoid pregnancy or fathering a child for the duration of study 
participation with the exception of  male and female participant s who are prepubescent.  
Note:   Female participants who have reached menarche must have a negative urine 
pregnancy test at the screening and baseline visits before the first application of study 
cream  on Day [ADDRESS_1091338] also take appropriate precautions to avoid pregnancy from  
the screening visit through the safety follow -up visit. 
10. Ability to comprehend and willingness to sign an ICF or written informed consent of the 
parent(s) or legal guardian and a verbal or written assent from the participant when 
possible.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. An unstable course of AD (spontaneously improving or rapi[INVESTIGATOR_166462]) as 
determined by [CONTACT_537700] 4 weeks before the  baseline  visit. 
2. Concurrent conditions and history of other diseases  as follows : 
a. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, 
Wiskott -Aldrich syndrome) or a history of malignant disease within 5 years before 
the baseline  visit. 
b. Chronic  or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit.  
c. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes 
zoster, chicken pox, clinically infected AD, impetigo) within 1 week before the 
baseline visit.  
d. Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton 
syndrome), pi[INVESTIGATOR_371], or extensive scarring that in the opi[INVESTIGATOR_791495].  
e. Presence of AD lesions only on the hands or feet without prior history of involvement 
of other classic areas of involvement such as the face or the flexural folds.  
f. Other types of eczema.  
g. Chronic asthma requiring more than 880 µg /day of inhaled budesonide or equivalent 
high dose of other inhaled corticosteroids.  
h. Any participant on maintenance dialysis.  
i. A medical history of hepatitis B virus or hepatitis C virus infection . 
3. Any of the following  clinical  laboratory test results  at screening : 
a. Removed during Protocol Amendment 2.  
b. Removed  (modified  and moved to Exclusion Criterion 3 d) during Protocol 
Amendment 2.  
c. Cytopenias at screening, defined as follows:  
− Hemoglobin < 10 g/dL  
− ANC < 1000/µL  
− Platelet count < 100,000/µL  
Incyte Corporation  Page 38 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  d. Liver function tests:  
− AST or ALT ≥ 2.5 × ULN  
− Total bilirubin >  1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if 
bilirubin is fractionated and direct bilirubin is <  35%)  
e. Estimated GFR < 30 mL/min/1.73 m2 (using the Modification of Diet in Renal 
Disease equation).  
f. Positive serology test results at screening for HIV antibody . 
g. Any other clinically significant laboratory result that, in the opi[INVESTIGATOR_1070], poses a significant risk to the participa nt. 
4. Removed (moved to Exclusion Criteri on 2i) during Protocol Amendment 2.  
5. Any serious illness or medical, physical, or psychiatric condition(s) that, in the 
investigator 's opi[INVESTIGATOR_1649], would interfere with full participation in the study, including 
administra tion of study cream  and attending required study visits; pose a significant risk 
to the participant; or interfere with interpretation of study data.  
6. Use of  any of the following treatments within the indicated washout period before the 
baseline visit:  
a. 5 hal f-lives or 12 weeks, whichever is longer – biologic agents (eg,  dupi[INVESTIGATOR_12458]).  
b. 4 weeks – systemic corticosteroids or adrenocorticotropic hormone analog ues, 
cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or 
immunomodulating agents  (eg, mycophenolate or tacrolimus).  
c. 2 weeks – immunizations with live-attenuated vaccines; sedating antihistamines 
unless on a long-term stable regimen (nonsedating antihistamines are permitted).  
Note:   Live-attenuated  vaccine s are not recommended during the VC period.  
Note:   COVID -19 vaccination is allowed . 
d. 1 week – use of topi[INVESTIGATOR_117928] (other than bland emollients, eg, Aveeno® 
creams, ointments, sprays, soap substitutes), such as topi[INVESTIGATOR_537679] s (eg, doxepin 
cream), corticosteroids, calcineurin inhibitors, PDE4 inhibitors, coal tar (shampoo), 
topi[INVESTIGATOR_8163], or antibacterial cleansing body wash/soap.  
Note:   Diluted sodium hypochlorite "bleach " baths are allowed as long as they do not 
exceed 2 baths per week  and their frequency remains the same throughout the study . 
7. Previous treatment with systemic or topi[INVESTIGATOR_73209] (eg,  ruxolitinib, tofacitinib, 
baricitinib, filgotinib, lestaurtinib, pacritinib).  
8. Ultraviolet light therapy or prolonged exposure to  natural or artificial sources of UV 
radiation (eg,  sunlight or tanning booth) within 2 weeks prior to the baseline visit and/or 
intention to have such exposure during the study, which is thought by [CONTACT_393605] 's AD. 
9. Removed (moved to Exclusion Criteri on 3f) during Protocol Amendment 2.  
10. Current treatment or treatment within 30  days or 5  half-lives (whichever is longer) before 
the baseline visit with another investigational medication or current enrollment in another 
investigational drug protocol.  
11. Removed during Protocol Amendment 4 . 
Incyte Corporation  Page 39 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  12. In the opi[INVESTIGATOR_871], unable or unlikely to comply with the administration 
schedule and study evaluations.  
13. Employees of the sponsor or investigator or otherwise depen dents of them.  
5.3. Lifestyle Considerations  
Prolonged exposure to natural or artificial sources of UV radiation (including sun lamps, tanning 
booths, etc) is prohibited from [ADDRESS_1091339] reconsent (if rescreened ≥  28 days after the 
initial scr eening  or ≥ 35 days after the initial screening for those participants on prior 
medications requiring a 4 -week washout period, as described in Section  5.2, Exclusion 
Criterion  6b) and be assigned a new screening number.  
5.5. Replacement of Participants  
Participants are not anticipated to be replaced during the study.  However, as noted in 
Appendix  C (COVID -19–related guidance),  due to the evolving situation of the COVID -19 
pandemic, the sponsor may decide to recruit additional participants in the study beyond the 
expected number  (eg, if a substantial number of participants withdraw early from the study).  
Incyte Corporation  Page 40 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  6. STUDY TREATMENT S 
See Appendix  C for COVID -19–related guidance.  
6.1. Study Treatment s Administered  
Table  8 presents the study treatment information.  
Table  8: Study Treatment Information  
 Study Treatment 1  Study Treatment 2  Study Treatment 3  
Study treatment na me: Ruxolitinib cream 1.5%  Ruxolitinib cream 0.75%  Vehicle  
Treatment  strength:  1.5%  0.75%  Not applicable  
Mechanism of action:  Inhibitor of the JAK 
family of protein 
tyrosine kinases  Inhibitor of the JAK 
family of protein  
tyrosine kinases  Not applicable  
Dosage formulation:  Cream  
Route of administration:  Topi[INVESTIGATOR_352902]:  VC period:  BID (morning and evening applications at least 1 hour before 
bedtime); a thin film is applied to affected areas.  
LTS period:  BID (morning and evening  applications 
at least 1 hour before bedtime); a thin film is applied 
to affected areas.  LTS period:  Not 
applicable.  
Packaging and labeling:  Ruxolitinib cream and vehicle cream will be provided in 60 -g tubes.  Each tube 
will be labeled as required per country requirements.  
Storage:  Ambient (15°C -30°C/59°F -86°F)  
Status of treatment in 
participating countries:  Investigational  Investigational  Not applicable  
Study treatments  (ruxolitinib cream 1.5%, ruxolitinib cream 0.75%, and matching vehicle  cream  
formulation that does not contain active drug ) will be supplied in 60 -g tubes and applied 
topi[INVESTIGATOR_178106] a thin film BID (optimally at equal intervals, eg, ideally  [ADDRESS_1091340] 8 hours between applications ) to the affected areas in the m orning and in the evening, with 
the evening application a t least 1 hour before bedtime.  
At the baseline visit, an estimate of the %BSA to be treated will be used by [CONTACT_791526].  All areas identified at the baseline 
visit should continue to be treated through the end of the VC period (at Week 8) , even if the area 
begins to improve or the AD resolves completely, unless the participant meets criteria for 
stoppi[INVESTIGATOR_500995] . 
If there are new areas to be treated, including expansion of existing areas or development of new 
areas, after consultation with the investigator, study cream  should be applied to these areas in 
addition to the areas identified  at the baseline  visit (up to 20% BSA)  for the remainder of the VC 
period , and the percentage of BSA to be treated will be recalculated and increased.  This new 
estimate will be entered into the IRT system to calculate the number of tubes of study cream  to 
be dispensed.   Approval to treat thes e additional areas may occur via telephone, although the 
investigator, at their discretion, may ask the participant to return for an unscheduled visit. This is 
a close reflection of the clinical practice of managing AD in the outpatient setting.   Participa nts 
Incyte Corporation  Page 41 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  whose additional new areas to be treated in addition to the areas identified at the baseline visit 
exceed 20% BSA should be discontinued from study treatment  and complete the EOT 
assessments . 
During the LTS period starting at the Week [ADDRESS_1091341] study visits every 
4 weeks until the end of the study (44  weeks total).  At those visits, AD lesions will be evaluated 
by [CONTACT_393610] 
(IGA  score ≥ 1) or can other wise (re)enter the observation/no treatment cycle (IGA  score  = 0).  
During this period, only areas with active disease need to be treated.  Participants who develop 
new or expanded areas of AD may treat these additional areas with approval by [CONTACT_791527] 20% and there are no safety concerns regarding 
the additional application of study cream .  At Week 8, each participant will receive a 
prespecified number of tubes of study cream  corresponding to a lower %BSA affected (up to 
5%) or higher number of tubes corresponding to their affected %BSA (> 5%).  This new estimate 
will be entered into the IRT system to calculate the number of tubes of study cream  to be 
dispensed.  
The start and end dates of treatment app lications will be captured by [CONTACT_2299].  Once the 
lesions clear, participants should continue to apply study cream  for an additional [ADDRESS_1091342] sign of recurrence.  
At any time during the LTS period , if a participant 's new areas to be treated in addition to the 
areas identified at the previous visit exceed 20% BSA, then the participant should be 
discontinued from study treatment  and complete the EOT assessments . 
No study treatment adjustments are allowed except for temporary drug discontinuation,  if needed 
(eg, for management of an AE ; see Section  6.5). 
6.1.1.  Study Treatment  Application Guidance  
Participants should remove Study Cream  from the tube  and apply the Study Cream  with their 
fingertip  in small amounts until all of the areas to be treated are covered by a thin , even film  (see 
Figure 8). 
Figure 8: Study Cream  Application Using a Fingertip  
 
Source:  DermNet New Zealand  (www.dermnetnz.org) . 

Incyte Corporation  Page 42 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  In the clinic, the amount of study cream  used will be determined by [CONTACT_17832] a tube(s) before 
and after the participant or guardian applies a thin film of study cream  to the affected areas.  
On the day of a visit,  the participant should not apply  their morn ing application of study cream  
at home; instead, study cream  will be applied in the clinic during the visit, under direct 
supervision of the site staff.  The tube will be weighed before and after application to determine 
the participant 's usage.  
Application instructions will be provided by [CONTACT_233528], and the participants will record 
their daily applications via a diary card provided at  each study visit.  Participants must  not apply 
study cream  more often than BID.  Refer to the Study Reference Manual for participant 
instructions for handling study cream . 
6.2. Preparation , Handling , and Accountability  
The investigator or designee must confirm appropriate temperature conditions (both ruxolitinib 
cream and vehicle cream are to be stored between 15°C and 30°C [59°F -86°F]) have been 
maintained during transit for all study treatments  received and any discrepancies are reported and 
resolved before use of the study treatment . 
Only participants enrolled in the study may receive study cream , and only au thorized site staff 
may distribute study cream .  The cream will be applied by [CONTACT_791528]/his parent /legal 
guardian .  Immediately after application of study cream , the hands  should be  thoroughly washed 
with soap and water.  Note  that the study cream  is for exclusive use on the skin.  In case of 
accidental exposure to the eyes or mucous membranes, the cream should be immediately 
removed from that area and necessary supportive measures taken.  Refer to the Study Reference  
Manual for participant in structions for handling of study cream . 
All study treatment  must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited 
to the investigator and autho rized site staff.  Participants should store study cream  at ambient 
temperature conditions.  
The investigator  or designee  is responsible for study treatment  accountability, reconciliation, and 
record maintenance (ie, receipt, reconciliation, and final dispo sition records) .  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_319853] .  The 
investigator or designee must maintain  records that document  the following : 
• Delivery of study cream  to the study site.  
• Inventory of study cream  at the site.  
• Participant use of the study cream , including  tube counts from each supply dispensed.  
• Return of study cream  to the investigator or design ee by [CONTACT_4317].  
The investigational product must be used only in accordance with the Protocol .  The investigator 
will also maintain records adequately documenting that the participants were provided the 
specified study cream .  These records should incl ude dates, quantities, and any available batch or 
serial numbers or unique code numbers assigned to the investigational product and study 
participants.  
Incyte Corporation  Page [ADDRESS_1091343] and retain all used, unused, and partially used containers of study cream  
until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_456]) .  At the 
conclusion  of the study, the investigator or designee will oversee shipment of any remaining 
study cream  back to the sponsor or its designee for destruction according to institutional SOPs .  
If local procedures mandate on -site destruction of the investigational supply, the site should 
(where local  procedures allow) maintain the investigational supply until the study monitor 
inspects the accountability records in order to evaluate compliance and accuracy of 
accountability by [CONTACT_3878] .  At sites where the study cream  is destroyed before  
monitor inspection, the monitors rely on documentation of destruction per the site SOP.  
Further guidance and information for the final disposition of unused study treatments  are 
included  in the  study materials provided to sites . 
6.3. Measures to Minimize Bias:   Randomization and Blinding  
All participants will be centrally assigned to study treatment  using an IRT system.  The system 
will assign in a 2:2:1 ratio, stratified by [CONTACT_740604] (2 or 3) and age, assign the 
participant study number, track partici pant visits, randomize according to the defined parameters, 
maintain the blinding, and manage study cream  inventory.  Full details will be provided in the 
IRT Manual.  Study treatment  will be dispensed at the study visits summarized in the SoA (see  
Table  3 and Table  4). 
6.4. Study Treatment Compliance  
Compliance will be assessed for frequency of administration of study cream  by [CONTACT_791529] s' diaries.  Participants will also be questioned regarding  study cream  application 
technique, missed applications, and use of any additional topi[INVESTIGATOR_500996] -the-counter products.  Compliance with study cream  will be evaluated by 
[CONTACT_2299] 's adherence to the BID application regimen (evaluation of actual number vs 
prescribed number of applications) and documented by [CONTACT_352966]/designee.  
Qualified clinical staff will review the diary entries for compliance.  Participants will be 
consid ered compliant with the treatment regimen if they apply at least 80% but no more than 
120% of the prescribed number of applications during participation in the VC period of the 
study.  Participants who are noncompliant during the VC period and LTS period ( if on a 
treatment cycle) will be reinstructed by [CONTACT_093] (or designee), and the sponsor should be 
consulted by [CONTACT_791530].  
Drug accountability will be assessed by [CONTACT_501032] (tube counts and weighing).  At the first clinic visit and subsequent study visits, the amount 
of study cream  to be applied is to be determined by [CONTACT_17832] a tube before and after the 
participant applies a thin film of study cream  to the affected areas.  Participants will be instructed 
to bring all study cream  with them to the study visits in order for site perso nnel to assess study 
cream  accountability.  
Incyte Corporation  Page 44 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  6.5. Dose Modifica tions 
Application adjustments/modifications (decrease or increase in study cream  strength or 
frequency of application) are not allowed except for  study cream  interruption or permanent 
discontinuation if needed (eg, for management of an AE).  
Temporary study cream  interruption could be due to an AE during the VC or LTS periods or due 
to clearance  of the AD lesions during the LTS period, as described in Section  6.1. 
6.5.1.  Criteria and Procedures for Application  Interruptions and Adjustments of 
Study Cream  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness 
to determine whether the participant should continue or discontinue study treatment.  
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs 
or laboratory abnormalities that may have an unclear relationship to study cr eam.  In the event of 
an AE is present at a specific site of application, treatment may be temporarily withheld only at 
that lesional site and continue d elsewhere .  This should be recorded as a dose interruption on the 
AE eCRF page .  Except in cases of eme rgency, it is recommended that any findings of concern 
(eg, AE) be confirmed and that the investigator consult with the sponsor medical monitor (or 
other representative of the sponsor) before interrupting study cream  applications .  Additionally, 
the invest igator must obtain approval from the sponsor before restarting study cream .  
Participants who experience a recurrence of the initial AEs upon restarting the study cream  may 
need to permanently discontinue  treatment with the study cream . 
Participants should  be closely monitored for the development of signs and symptoms of infection 
during treatment with the study cream  and up to the safety follow -up visit. Study cream  should 
be interrupted if a participant develops a serious infection, an opportunistic infec tion, or sepsis. 
Study cream  application should not be resumed until the infection is controlled.  
Instructions for application interruptions of study cream  are outlined in Table  9.  Individual 
decisions regarding interruptions should be made using clinical judgment in consultation with the 
medical monitor (whenever possible), taking into account relatedness of the AE to the study 
cream  and the participant 's underlying condition.  
Incyte Corporation  Page 45 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  9: Guidelines for Interruption and Restarting of Treatment Applications if 
Adverse Event I s Deemed Related to the Study Cream  
Adverse Event Related to Study Creama Action Taken  
ANC  < 750/µL (without fever); <  1000 /µL (with 
fever)  • Laboratory abnormalities should be confirmed 
with repeat testing within 48 hours whenever 
possible and immediate delivery of the 
laboratory  results requested.  
• Study cream  applications must be interrupted.   
At the discretion of the investigator, after 
consultation with the sponsor, study cream  
application may be restored once these have 
resolved.  
Any other Grade 3 or higher laboratory 
abnormality (eg, hemoglobin with the exception of 
asymptomatic elevations in triglyceride, 
cholesterol, or amylase)  • Laboratory abnormalities should be confirmed 
with repeat testing within 48 hours whenever 
possible and immediate delivery of the 
laboratory results requested.  
• Study cream  applications must be interrupted.    
At the discretion of the investigator, after 
consultation with the sponsor, study cream  
application may be restored once these have 
resolved.  
Any Grade [ADDRESS_1091344] or 
ALT (>  20 × ULN)  • Laboratory abnormalities should be confirmed 
with repeat testing within 48 hours whenever 
possible and immediate delivery of the 
laboratory results requested.  
• Discontinue study cream  if laboratory 
abnormalities are confirmed.  
a In the opin ion of the in vestigator . 
6.5.2.  Criteria for Permanent Discontinuation of Study Cream  Due to an Adverse 
Event  
The occurrence of unacceptable severity of an AE not caused by [CONTACT_791531].  Unacceptable severity is defined as follows:  
• Occurrence of an AE that is related to treatment with the study cream  that, in the 
judgment of the investigator or the sponsor 's medical monit or, compromised the 
participant 's ability to continue study -specific procedures or is considered to not be in 
the participant 's best interest.  
• Participant presents with a worsening of AD that requires treatment with a prohibited 
concomitant medication.  
• Persistent AE requiring a  delay of therapy for more than 2 weeks without resolution 
of the AE.  
• Any Grade 4 laboratory abnormality related to the study cream  (see Table  9). 
See Section  7 for discontinuation procedures.  
Incyte Corporation  Page 46 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  6.6. Concomitant Medications and Procedures  
All concomitant medications and treatments ( including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF.  Any 
prior medication received up to [ADDRESS_1091345] application of study treatment  
should be recorded for SAEs as defined in Section  9.3.  Concomitant treatments/procedures that  
are required to manage a participant 's medical condition during the study will also be recorded in 
the eCRF.  The medical monitor should be contact[CONTACT_61519].  
6.6.1.  Permitted Medications and Procedures  
The following are permitted during the study:  
• Participants may use bland emollients (except those containing urea, salicylic acid , or 
lactic acid) such as Eucerin® cream.   Participants should continue to use the bland 
emollient/moisturizer in the same manne r they did before entering the study and 
throughout the course of the study.  
Note:   Emollients should not be used within 4  hours before and 2 hours after 
application  of study cream . 
• Bathing during the study should be limited to once daily for no longer tha n 
15 minutes  and not within 2 hours following study cream  application .  During baths, 
tepid (not hot) water and mild cleansing agents (eg, Basis® bar or Dove®) should be 
used.  (See Section  5.3 for swimming guidance.)  Showers should be limited in time 
with warm water and mild cleansing agents used.  
• If sunscreen is needed, a mineral -based sunscreen (such as zinc oxide – or titanium 
oxide–based) with SPF of at least [ADDRESS_1091346] 2  hours after study cream  application.  
• Participants may use nonsedating, over -the-counter antihistamines.  
6.6.2.  Restricted Medications and Procedures  
The following are permi tted during the study under specified conditions:  
• Short -term use of systemic corticosteroids may be permitted to treat acute AEs 
(eg, asthma, croup) during the LTS period, and the decision to keep the participant in 
the study (or to permanently discontinue  study cream) will be made in consultation 
with the medical monitor.  
• Participants may continue using sedating  antihistaminic drugs as long as their use is 
part of a preexisting and well-established regimen .  There are no restrictions for use 
of nonsedating  antihistamines.  
Incyte Corporation  Page 47 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • Use of any over -the-counter, nonprescription preparations deemed acceptable by [CONTACT_791532] . 
• Use of any prescription medication (including phytotherapeutic, herbal, or 
plant-derived preparations) within 7 days before the baseline visit through the safety 
follow -up visit , unless deemed acceptable by [CONTACT_093].  
• Immunizations with a live-attenuated  vaccine  are not recommended during the VC 
period (first 8 weeks) unless d eemed necessary by [CONTACT_093].  
• Allergen immunotherapy (desensitization) that is ongoing at a stable dose at the time 
of study entry may be continued while on study but only at the same dose . 
• Bleach baths are allowed as long as they do not exceed 2 ba ths per week and their 
frequency remains the same throughout the study.  
• Participants should not take baths or showers within 2 hours after study cream  
application.  
• Topi[INVESTIGATOR_900] -infectives or other topi[INVESTIGATOR_393582] 4 hours before and 2 hours after application of study cream . 
6.6.3.  Prohibited Medications and Procedures  
The following are not permitted during the s tudy:  
• Any investigational medication other than the study cream . 
• Topi[INVESTIGATOR_11930], tacrolimus, pi[INVESTIGATOR_031], and PDE4 -inhibitors (Eucrisa).  
• Other topi[INVESTIGATOR_393583] (except bland emollients as noted in Section  6.6.1 ). 
• Treatment known to affect the course of AD.  
• Systemic corticosteroids  (except the example stated in Section  6.6.2 ), methotrexate, 
cyclosporin A, azathioprine and biologic therapi[INVESTIGATOR_014], or other immunosuppressant 
agents.  
• Phototherapy or tanning beds.  
6.7. Treatment After the End of the Study  
There will be no treatment provided after t he end of the study.  
Incyte Corporation  Page [ADDRESS_1091347]  be discontinued from study treatment for the following reasons:  
• Lack of efficacy response during the LTS period (defined as no change/improvement 
in either %BSA or IGA when treated continuously for 8 weeks).  
• AD worsens  during either the VC period or the LTS period, to the point where the  
extent of AD to be treated (ie. all areas excluding the scalp) exceed s 20% BSA.  
• The participant becomes pregnant.  
• Consent is withdrawn.  
Note:   Consent withdrawn means that the participant has explicitly indicated that 
he/she does  not want to be followed any longer; in this case , no furth er data, except 
data in the public domain, may be solicited from or collected on the participant.  
Participants may choose to discontinue study treatment and remain in the study to be 
followed for safety monitoring.  
• Further participation would be injurious  to the participant 's health or well -being, in 
the investigator 's medical judgment.  
• Any AE of unacceptable severity as noted in Section  6.5.2 . 
• The st udy is terminated by [CONTACT_456].  
• The study is terminated by [CONTACT_19407], IRB, or IEC.  
A participant  may be discontinued from study treatment as follows:  
• If, after 2 consecutive study visits  and reinforcement of study cream  application by 
[CONTACT_6624] , a participant 's drug usage exceeds one 60 -g tube every 4 days, a participant 
who again fail s to meet compliance benchmarks at a subsequent visit may be 
considered for withdrawal from the study .  The medical monitor should be con sulted 
for instruction on handling the participant.  
• If, during the course of the study, a participant is found not to have met eligibility 
criteria, the medical monitor, in collaboration with the investigator, will determine 
whether the participant should be withdrawn from study treatment.  
• If a participant is noncompliant with study pr ocedures or study cream  administration 
in the investigator 's opi[INVESTIGATOR_1649], the medical monitor should be consulted for instruction 
on handling the participant.  
Incyte Corporation  Page 49 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  7.1.2.  Discontinuation Proc edures  
In the event that the decision is made to permanently discontinue the study treatment  prior to the 
Week 52/EOT study visit , the ET visit should be conducted.  Reasonable efforts should be made 
to have the participant return for a follow -up visit.  T he date of the last  application of study 
cream  and the reason for discontinuation of study cream  will be recorded in the eCRF.  
If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified.  
• The reason(s) for withdrawa l must be documented in the participant 's medical record 
and the primary reason for withdrawal must be included in the eCRF.  
• The ET visit should be performed.  
• The date of the ET visit should be recorded in the eCRF.  
• Participants must be followed for safety until the time of the follow -up visit or until 
study treatment –related AEs resolve, return to baseline, or are deemed irreversible, 
whichever is longest.  
If the participant discontinues study treatment and actively withdraws consent for collection of 
follow -up data (safety follow -up), then no additional data collection should occur; however, 
participants will have the option of withdrawing consent for study treatment but continuing in the 
follow -up period of the stud y for safety assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
admini strative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  If a participant 
withdraws from the study, he/she may request d estruction of any samples taken and not tested, 
and the investigator must document this in the site study records.  
Data to be collected at the time of study discontinuation and follow -up and for any further 
evaluations should conform to the requirements of  the ET/EOT visit (see Table  3 and Table  4). 
7.3. Lost to Follow -Up 
A participant  will be considered lost to follow -up if he/she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  The following actions must be 
taken if a participant fails to return to the clinic for a required study visit:  
• The site must attempt to contact [CONTACT_791533]/or 
should continue in the study.  
Incyte Corporation  Page 50 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • Before a part icipant is deemed lost to follow -up, the investigator or designee must 
make a reasonable effort to regain contact [CONTACT_6635] (where possible, 
3 telephone calls and, if unsuccessful, a certified letter to the participant 's last known 
mailing addre ss or local equivalent methods).  These contact [CONTACT_19425] 's medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
8. STUDY ASSESSMENTS AN D PROCEDUR ES 
See Appendix  C for COVID -19–related guidance.  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions 
regarding the study.  
− Informed consent /assent  must be obtained before any study -related procedures are 
conducted, un less otherwise specified by [CONTACT_89191].  
− Informed consent /assent  must be obtained using the IRB/IEC -approved version in 
a language that is native and understandable to the participant.  A template will be 
provided by [CONTACT_3552].  The spon sor or its designee must review 
and acknowledge the site -specific changes to the ICF /assent  template.  The ICF 
must include a statement that the sponsor or its designee and regulatory 
authorities have direct access to participant records.  
− The ICF must cont ain all required elements and describe the nature, scope, and 
possible consequences of the study in a form understandable to the study 
participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authoriz ed representative will be required to sign a statement of informed 
consent/assent that meets the applicable requirements and regulations for the 
countries in which the study is being conducted as well as the IRB/IEC or study 
center.  
• The participant must be  informed that his/her personal study -related data will be used 
by [CONTACT_89192].  The level of disclosure 
must also be explained to the participant.  
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
Incyte Corporation  Page 51 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • The medical record must include a statement that written informed consent/assent 
was obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF/assent.  
• Participants must provide consent to the most c urrent version of the ICF(s)/assent(s) 
during their participation in the study.  
• A copy of the signed ICF(s)/assent(s) must be provided to the participant or the 
participant 's legally authorized representative.  
• Participants who are rescreened are required t o sign a new ICF/assent (if rescreened 
> 28 days after the initial screening  [or > 35 days for participants on prior 
medications re quiring a 4 -week washout period as described in Section  5.2, Exclusion 
Criterion 6b ]) and must be assigned a new participant number.  
8.1.2.  Screening Procedures  
Screening is the interval between signing the ICF/assent and the day the participant is enrolled in 
the study (Day  1).  Informed consent (or assent) must be obtained before performing any 
study -specific procedures.  Screening assessments for determination of eligibility may be 
performed over a period of up to  28 days , or up to 35 days for participants on prior medications 
requiring a 4 -week washout period  as described in Section  5.2 (Exclusion Criterion 6b) .  
Assessments that are required to demonstrate eligibility may  be performed over the course of 
[ADDRESS_1091348] recent available laboratory result s 
before randomization/treatment assignment will be us ed to determine eligibility.   Additionally, a 
participant who fails screening may repeat the screening process 1  time if the investigator 
believes that there has been a change in eligibility status (eg, after recovery from an infection).  
The participant i s not required to sign another ICF if the rescreening occurs within 28  days (or 
35 days for participants on prior medications requiring a 4 -week washout period ) of the previous 
ICF signature [CONTACT_568]  (screening period) . 
See Section  5.[ADDRESS_1091349] the IRT system to 
obtain the participant ID number during screening.  Upon determining that the partici pant is 
eligible for study entry, the IRT system will be contact[CONTACT_352940].  Additionally, the IRT system will be contact[CONTACT_791534]  3 and Table  4 to update the study 
cream  supply.  The IRT system will also be used during the study visits to recalculate the amount 
of study cream  to be dispensed if the participant 's %BSA of AD lesions to be treated has 
Incyte Corporation  Page 52 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  increased (during the VC period) or has either increased or decreased (dur ing the LTS period).  
Additional details are provided in the IRT Manual.  
8.1.4.  Distribution of Reminder Cards and Diaries  
Starting at Day 1 visit and each visit thereafter, a study cream –specific diary will be given to 
each participant in order to record use of the study cream .  The completed diary will be reviewed 
during each of the participant 's study visits  and data uploaded will be confirmed by [CONTACT_8702]. 
Qualified clinical study  staff will review the participants ' entries for compliance.  Participants 
who are noncompliant with their study cream  schedule (defined as < 80% or > 120% of the 
expected number of applications between study visits) will have their administration instructions 
reinforced by [CONTACT_1720] a qualified designee.  Participants will be considered compliant 
with the treatment regimen if they apply at least 80% but no more than 120% of the expected 
applications during participation in the VC period of the study.  
Participants will be provided with a reminder card starting on Day [ADDRESS_1091350] been 
completed.  
8.1.5.  Demography and Medical History  
[IP_ADDRESS].  Demographics and General Medical History  
Demographic data and general medical history will be collected at screening by [CONTACT_791535]/age, race, ethnicity, medical and surgical 
history, and current illnesses.  Medical history will include relevant medical or surgical treatment 
within the past 2 years that are considered to be clinically significant by t he investigator.  
The height and weight of both parents, if available, should be obtained and entered into the EDC.  
[IP_ADDRESS].  Medical  and Treatment History  
Relevant medical and treatment history for the past year will be collected at screening by [CONTACT_100924].  Details regarding the participant 's history of AD, including 
date of diagnosis, relevant disease characteristics, and prior treatments  for the previous year prior 
to enrollment , including systemic treatments, radiation, and surgical pr ocedures, will be 
recorded.  Acceptable documentation includes contemporaneous chart notes that record topi[INVESTIGATOR_12851], or investigator documentation based on 
communication with the participant's  treating physician.  A medical history of other conditions 
related to AD will also be collected at this time.  
In addition, information about previous AD treatment (within 12 months prior to screening) and 
their outcomes will be collected.  For participants with safety issues (s ide effects) and/or 
insufficient therapeutic response, a collective term of inadequate response will be used.  
Inadequate response is defined as inability of a given topi[INVESTIGATOR_791496] (comparable to IGA score of 

Incyte Corporation  Page 53 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  0-2; none to mild eczema lesions ) despi[INVESTIGATOR_791497] h a topi[INVESTIGATOR_441073] 
a topi[INVESTIGATOR_73199] (if applicable) for at least [ADDRESS_1091351] prescribing information (whichever is shorter).  
Participants with documented systemic treatment for AD can also be considered as inadequate 
responders to topi[INVESTIGATOR_12969].  
Clinically relevant side effects/safety risks and/or skin tolerability issues are those that outweigh 
the potential treatment benefits and are the reason why a topi[INVESTIGATOR_791498].  
8.2. Efficacy Assessments  
8.2.1.  Health Economics  
Not applicable.  
8.2.2.  Body Surface Area  
Total %BSA affected  by [CONTACT_501036] (see Table  3 
[VC period] and  Table  4 [LTS period] ).  Body surface area assessment will be approximated to 
the neares t 0.1% using the handprint (Palmar) method as a guide.  The approximate size of the 
participant 's entire palmar surface (ie, the palm plus 5 digits, with fingers tucked together and 
thumb tucked to the side) should be considered as 1% BSA, and the approxim ate size of the 
participant 's thumb should be considered as 0.1% BSA.  
Alternatively, %BSA affected by [CONTACT_791536], based on age group, in  Appendix  D.  One of these [ADDRESS_1091352] BSA involvement (excluding scalp) of 3% to 20% at the screening and 
baseline visits for the VC period to enroll in the study; they may have 0% to 20% BSA 
involvement at Week 8 ( baseline for the LTS period) to enter the LTS period.  
During the LTS period, including Week 8 (baseline for the LTS period), %BSA will be 
evaluated by [CONTACT_791537] (re)enter an observation/no treatment cycle.  
8.2.3.  Target Lesion Identification  
A representative target lesion for participants who consent to photography will be identifie d 
during the screening  visit, and the measurements of the same lesion will be confirm ed/updated  at 
the baseline  visit (procedure is optional for nonphotography participants). The target  lesion 
should be  representative of the participant 's overall disease a nd is to be treated with study cream .  
The target lesion should approximately measure at least 5 cm2 in size and should not be on the 
hands, feet, or genitalia.  A note should be made in the participant 's source documents , and the 
photographs  (at selected sites)  can be marked with the location of the target lesion at each visit.  
The longest diameter and the span perpendicular to the longest diameter will be measured in 
centimeters.  
Incyte Corporation  Page 54 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  8.2.4.  Photography  
At selected sites , participants will be asked but will not be required to consent to photography .  
For each visit with photography (baseline and Weeks 2, 4, and 8), a photograph of the target 
lesion (identified at the baseline  visit, at least 5 cm2 in size; see Section  8.2.3 ) will be taken via 
2 views (close -up and regional body area)  before any study procedure , even if the AD lesion has 
cleared or disappeared.  A note should be made  in the partici pant's source documents  of the 
target lesion location , and the photograph s can be marked with the location of the target lesion at 
each visit.  
8.2.5.  Investigator 's Global Assessment  
Investigator 's Global Assessment is an overall eczema severity rating on a 0 to 4 scale that will 
be assessed during site visits  as outlined in the SoA (see Table  3 [VC period] and  Table  4 [LTS 
period] ).  The severity strata for the IGA are shown in  Table  10. 
Table  10: Investigator 's Global Assessment  
Grade  Severity  Status  
0 Clear  No erythema or induration/papulation, no oozing/crusting; there may be minor 
residual discoloration  
[ADDRESS_1091353] no induration/papulation, and no 
oozing/crusting  
2 Mild  There may be faint pi[INVESTIGATOR_80169], with mild induration/papulation and no 
oozing/crusting  
3 Moderate  There may be pi[INVESTIGATOR_8745] -red erythema with moderate induration/papulation and there may 
be some oozing/crusting  
4 Severe  There may be deep or bright red erythema with severe induration/papulation and with 
oozing/crusting  
Source:  FDA  2012 . 
The IGA -TS is defined as an IGA score of 0 or 1 with  a ≥ 2-grade improvement from baseline.  
Participants must have an IGA score of 2 or 3 at the screening and baseline visits for the VC 
period  to enroll in the study; they may have an IGA score of 0 to 4 at Week 8 ( baseline for the 
LTS period) to enter the LTS period.  
During the LTS period, including Week 8 (baseline for the LTS period), IGA will be evaluated 
by [CONTACT_791538] (re)enter an observation/no treatment cycle.  If the IGA score is ≥  1, the participant will 
start or continue active treatment with ruxolitinib cream (0.75% or 1.5%) BID.  If the IGA score 
is 0 (clear), the participant will (re)enter an observation/no treatment cycle.  
8.2.6.  Eczema Area and Severity Index  
Atopic dermatitis will be assess ed as outlined in the SoA (see Table  3) using the EASI scoring 
system, which is a validated scoring system that grades the physical signs of AD to provide a 
measure of AD severity (ranging from 0 to 72).  The EASI scoring system examines 4 regions of 
the body (head/neck, upper limbs, trunk, and lower limbs) and weights them.  Each of the 4 body 
regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations 
(Ex), and lichenification (L) for an average degree of severity of each sign in each region.  The 
Incyte Corporation  Page 55 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  multiplier used in the scoring is based on age (<  8 years or ≥  8 years).  See Appendix  E for the 
EASI calculation guides  by [CONTACT_551] . 
The severity strata for the EASI are as follows:  0 = clear; 0.1  to 1.0 = almost clear; 1.1 to 
7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; and 50.1 to 72.0 = very severe.  
8.2.7.  Itch Numerical Rating Scale  
The Itch NRS will be administered based on the participant 's age  (at the time of consent) , as 
follows:  
• For participants ≥  [ADDRESS_1091354] the Itch NRS.   Baseline itch  (defined as the 
average of the [ADDRESS_1091355] 4 of the 7 days ) must be ≥  4 on NRS.  
• For participants <  [ADDRESS_1091356] the Itch NRS.  
The Itch NRS is a daily participant -reported measure (24 -hour recall) of the worst level of itch 
intensity  (Pruritus Resources ).  Participants will be asked to rate the itch severity of their AD b y 
selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst 
level of itching in the past 24 hours as outlined in the SoA (see Table  3).  Participants will be 
issued a diary in which to record itch severity.  The participants will be instructed to complete 
the diary each night beginning on the day of screening through the last application of study 
cream  during  the VC period.  This is particularly important for the 7 days immediately prior to 
the Day 1/ baseline , Week 2, Week 4, and Week 8 visits; therefore, Itch NRS scores are required 
for at least 4 of those 7 days during each of these 4 weeks to allow evaluation o f participant 
eligibility and the Itch NRS endpoints. Detailed directions for the administration of a diary will 
be provided in the Study Reference Manual.  

Incyte Corporation  Page 56 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  

Incyte Corporation  Page 57 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  

Incyte Corporation  Page 58 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  8.4. Safety Assessments  
Planned timepoints for all safety assessments are provided in the SoA ( see Table  3 [VC period] 
and Table  4 [LTS period]).  

Incyte Corporation  Page 59 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  See Section  6.5 for guidelines regarding the management of relevant l aboratory or other safety 
assessment abnormalities.  
8.4.1.  Adverse Events  
Adverse events will be monitored from the time the participant signs the ICF  (or assent)  until at 
least [ADDRESS_1091357] application  of study cream .  Adverse events that begin or wors en after 
informed consent should be recorded on the Adverse Events Form in the eCRF  regardless of the 
assumption of a causal relationship with the study cream .  Conditions that were already present 
at the time of informed consent should be recorded on the Medical History Form in the eCRF .  
Adverse events (including laboratory abnormalities that constitute AEs) should be described 
using a diagnosis whenever possibl e rather than by [CONTACT_147108].  
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized representative) .  The investigator and any 
qualified des ignees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following  up on AEs that are serious, 
considered related to the study cream /procedures, or that caused the participa nt to discontinue the 
study cream .  Care will be taken not to introduce bias when detecting AEs and/or SAEs .  
Open -ended and nonleading verbal questioning of the participant, such as "How are you 
feeling? ", is the preferred method to inquire about AE  occur rences .  Adverse events may also be 
detected when they are volunteered by [CONTACT_501039] s, laboratory test s, or other assessments .  The definition, 
reporting, and recording req uirements for AEs are described in Section  9. 
All SAEs will be reported to the sponsor or designee within 24 hours .  The investigator will 
submit any updated SAE data to the sponsor within 24 hours of it being available.  
After the initia l AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts .  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as de fined in Section  7.3). 
8.4.2.  Physical Examinations  
During the study, participants will be assessed by [CONTACT_791539] .  Physical examinations will be conducted at the 
timepoints listed in Table  3 and Table  4. 
[IP_ADDRESS].  Comprehensive Physical Examination  
At the screening  visit and Week 52/EO T or ET  visit, a comprehensive physical examination 
should be conducted.  The comprehensive physical examination will include assessment(s) of the 
following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular sy stem; abdomen (liver, spleen); extremities; and lymph nodes; as well as a brief 
neurological examination.  
[IP_ADDRESS].  Targeted Physical Examination  
At the visits  indicated in the SoA (see Table  3 [VC period] and Table  4 [LTS period]) , a targeted 
physical examination will be a symp tom-directed evaluation (ie, conducted only if indicated by 
[CONTACT_791540] 60 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  symptoms, AEs, or other findings ); clinically significant abnormalities (in the investigator 's 
judgment) are to be reported as AEs  and documented on the Adverse Events Form in the  eCRF . 
8.4.3.  Vital Sign s, Height, and Weight  
Vital signs, height, and weight will be measured as outlined in the SoA (see Table  3 [VC period] 
and Table  4 [LTS period]).  
Vital sign measurements (to be taken before bl ood collection for laboratory tests) include blood 
pressure, pulse, respi[INVESTIGATOR_697], and body temperature.  Blood pressure and pulse will be taken 
with the participant in the sitting position after [ADDRESS_1091358] application of study cream  constitute an AE if they are considered 
clinically meaningful, induce clinical signs or symptoms, or require concomitant therapy.  
Height and weight will be assessed at the baseline , Week 8 /ET, Week 24 , and Week  52/EOT/ET  
visits .  Individual growth measurements from the preceding year should be collected , if at all 
possible, from each participant 's physician prior to the baseline visit.   If these measurements 
cannot be  obtain ed, the reason  should be documented .  Height will b e measured using a 
stadiometer .  The stadiometer should be calibrated , and a wall-mounted  one is recommended .  
Participants should be measured without socks and [ADDRESS_1091359] each 
participant's growth measurements from the previous year prior to entry into this trial . 
8.4.4.  Laboratory Assessmen ts 
See Table  [ADDRESS_1091360] of clinical laboratory tests to be performed and the SoA (see Table  3 and 
Table  4) for the timing and frequency.  Day 1 testing will be performed only if t he interval 
between this visit and screening is >  2 weeks.   A central laboratory will perform all clinical 
laboratory assessment s for safety (blood chemistries and  hematology assessments)  
  Additional testi ng may be required by [CONTACT_537715].  All Protocol -required laboratory assessments must be conducted in 
accordance with the Laboratory Manual  and the SoA (see Table  3 and Table  4).  Information 
regarding collection, processing, and shippi[INVESTIGATOR_791499].  
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by [CONTACT_41411] 's condition.  All laboratory tests with values considered clinically significantly 
abnormal during participation in the study, or within [ADDRESS_1091361] application of study 
cream , should be repeated until the values return to normal or baseline  or are no longer 
considered clinically significant by [CONTACT_10982].  
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  

Incyte Corporation  Page 61 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Table  11: Required Laboratory Analytes  
Serum Chemistrie s Hematology  Serology  
• Albumin  
• Alkaline phosphatase  
• ALT  
• AST  
• Bicarbonate  
• Blood urea nitrogen or urea  
• Calcium  
• Chloride  
• Creatinine  
• Glucose  
• Lactate dehydrogenase  
• Phosphorus  
• Potassium  
• Sodium  
• Total bilirubin  
• Direct bilirubin (if total bilirubin is 
elevated above  ULN)  Complete blood count, including:  
• Hemoglobin  
• Hematocrit  
• Mean corpuscular volume  
• Platelet count  
• Mean platelet volume (MPV)  
• Red blood cell count  
• Reticulocyte count  
• White blood cell count  
 
Differential count, including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  • HIV antibody  
Pregnancy Testing  
Female participants who have 
reached menarche will have a 
urine test conducted at all 
required visits.  A positive urine 
test must be confirmed by a 
serum test.  
Note:  Additional tests may be required, as agreed upon by [CONTACT_86206], based on emerging safety data or to rule 
out a diagnosis.  
  
 
 
. 
[IP_ADDRESS].  Pregnancy Testing  
A urine  pregnancy test will be required for all female particip ants who have reached menarche.  
The urine pregnancy test will be performed locally as outlined in the SoA (see Table  3 and 
Table  4), and as medically indicated (eg, in case of loss of menstrual cycle, whe n pregnancy is 
suspected).  If a urine pregnancy test is positive, the results must be confirmed with a serum 
pregnancy test.   Day 1 testing will be performed only if the interval between this visit and 
screening is >  [ADDRESS_1091362] was positive, the investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant 's best 
interest to resume study treatment and continue participation in the study.  
If a pr egnancy is confirmed by a serum pregnancy test, see Section  9.6 for reporting 
requirements.  
[IP_ADDRESS].  Serology  
An HIV assessment will be performed at the scree ning visit to rule out HIV infection; required 
analytes are shown in Table  11.  Serology and virology tests should be performed early in the 

Incyte Corporation  Page 62 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  screening process due to the length of time needed to obtain the results.  Additional tests may be 
performed if clinically indica ted. 
  
  
  
8.7. Unscheduled Vi sits 
Unscheduled study visits may occur at any time medically warranted , including when 
participants develop new areas of AD.  Any assessments performed at those visits should be 
recorded in the eCRF.  

Incyte Corporation  Page 63 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  If the participant develops new areas of AD, documentat ion of the new BSA may occur at an 
unscheduled visit if appropriate.  
8.8. End of Treatment  and/or Early Termination  
The EOT coincides with the Week 52 visit.  A participant that completes the Week 52/EOT visit 
will have reached the end of treatment  with study c ream . 
If a decision is made that the participant will permanently discontinue study cream  prior to the 
Week  52/EOT  visit, then the ET visit should be conducted.  If the ET visit coincides with a 
regular study visit, then the ET evaluations will supersede those of that scheduled visit, and the 
data should be entered in the ET page in the eCRF.  If this decision does not coincide with a 
regular visit, reasonable efforts should be made to have the participant return to the site to have 
the ET procedures compl eted.  
8.9. Follow -Up 
8.9.1.  Safety Follow -Up 
The safety follow -up period is the interval between the Week 52/ EOT  or ET  visit and the 
scheduled follow -up visit, which should occur 30  days after the Week 52/ EOT  or ET  visit, with 
the following 2 exceptions:  
• Follow -up vis it should occur a t the Week 52/EOT visit for participants who have 
been in an observation/no treatment cycle with an IGA score of 0 (clear) from 
Week  48 or earlier until Week 52  
• Follow -up visit should occur [ADDRESS_1091363] application of study cream  if the 
Week 52/ EOT  or ET  visit was not performed.  
Adverse events and SAEs must be reported up until [ADDRESS_1091364] application of study 
cream ; ongoing AEs and SAEs must be followed  up until toxicities resolve, return to baseline, or 
are deemed irr eversible, whichever is longer .  Reasonable efforts should be made to have the 
participant return for the follow -up visit and report any AEs that may occur during this period . 
Incyte Corporation  Page 64 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND REPOR TING  
9.1. Definition of Adverse Event  
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not it is considered drug -related.  
• An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study 
cream . 
Additional Guidance for Events Meeting the Adverse Event Defi nition  
• Any safety assessments (eg, vital sign measurements), including those that worsen from baseline, 
considered clinically significant in the medical and scientific judgment of the investigator (ie, not 
related to progression of underlying disease) are  to be reported as an AE.  
• Abnormal laboratory test results are to be reported as an AE if they are considered clinically 
meaningful, induce clinical signs or symptoms, require concomitant therapy, or require changes in 
study cream .  Whenever possible, a di agnosis (eg, anemia, thrombocytopenia) should be recorded in 
the eCRF rather than the abnormal laboratory test result (eg, low hemoglobin, platelet count 
decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition/disease, including either  an increase 
in the frequency and/or intensity of the condition, is to be reported as an AE.  
• New conditions detected or diagnosed after the start of study cream  administration are to be reported 
as an AE.  
• Signs, symptoms, or the clinical sequelae of a susp ected drug -drug interaction are to be reported as 
an AE.  
• Signs and/or symptoms from dosing errors of a study cream  (eg, overdose) or a concomitant 
medication are to be reported as an AE.  
• "Lack of efficacy " or "failure of expected pharmacological action " will not be reported as an AE or 
SAE.  Such instances will be captured in the efficacy assessments.   However, the signs, symptoms, 
and/or clinical sequelae resulting from lack of efficacy will be reported as an AE or SAE if they 
fulfill the definition of an AE or SAE.  
• A condition that leads to a medical or surgical procedure (eg, endoscopy, appendectomy) will be 
reported as an AE if it occurs after obtaining informed consent.  If the condition is present before 
entering the study, then it should be captured a s medical history.  
• Pre-existing diseases or conditions with expected fluctuations in signs or symptoms should be 
reported as an AE only if the investigator judges the fluctuation to have worsened more than 
expected during study participation.  
Incyte Corporation  Page 65 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  9.2. Definition o f Serious Adverse Event  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due 
to progression of disease).  
A serious adver se event is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term "life-threatening " in the definition of "serious " refers to an adverse drug experience that 
places the participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse 
experience as it occurs.  This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have caused death . 
c. Requires inpatient hospi[INVESTIGATOR_791500], hospi[INVESTIGATOR_19949] (involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate i n the physician 's office or outpatient setting.  Complications that occur during 
hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether hospi[INVESTIGATOR_791501], the AE 
should be considered serious.  
Hospi[INVESTIGATOR_312323] (eg, stent replacement, hip surgery) is not 
considered an SAE.  
Hospi[INVESTIGATOR_791502] 
(ie, elective procedures or routine medical visits) are not considered SAEs.  
d. Results in persistent or significant disability/incapacity  
• The term "disability " means a substantial disruption of a person 's ability to conduct normal life 
functions.  This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental 
trauma (eg,  sprained ankle), that may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is an important medical event  
An important medical event is an event that may not result in death, be immediately life -threatening, or 
require hospi[INVESTIGATOR_49200], based on appropriate medical judgment, 
the event may jeopardize the participant and may require medical or surgical intervention to prevent 
one of the outcomes listed in the above definition.   Examp les of such events include new invasive or 
malignant cancers ; intensive treatment in an emergency department or at home for allergic 
bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059] ; or development of 
drug dependency or drug abuse . 
Incyte Corporation  Page 66 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse 
Events  
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event Form in the eCRF.  Adverse events/ SAEs s hould be reported for enrolled participants, 
but only SAEs need to be reported for screen failure participants .  Conditions that were present at the 
time informed consent /assent  was given should be recorded on the Med ical History Form in the 
eCRF.  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_791503], laboratory reports, and diagnostic reports) related to the event.  
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914] 's medica l records 
in lieu of completing the Adverse Event Form in the eCRF.  
• There may be rare instances when copi[INVESTIGATOR_63475].  In this 
case, all participant identifiers, with the exception of the participant number, will b e redacted by [CONTACT_312366][INVESTIGATOR_205886] .  These records can be submitted to 
Incyte Pharmacovigilance by [CONTACT_6968]/fax per the contact [CONTACT_791541].  
• The investigator will attempt  to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) 
will be documented as the AE/SAE.  When a clear diagnosis cannot be identified, each s ign or 
symptom should be reported as a separate AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine the following:  
• The severity grade (CTCAE v5.0 Grade 1 to 5).  See below for further instructions on the assessment 
of intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study cream :  suspected 
(yes) or not suspected (no).  See below for further instructions on the assessment of causality.  
• The start and end dates, unless unresolved at the final safety follow -up visit. 
• The action taken with regard to study cream  as a result of the AE/SAE(s).  
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
• The seriousnes s, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event.  Note:  If an AE is treated with a concomitant medication 
or nondrug therapy, this action should be recorded on the Adverse Event Form and the treatment 
should be specified on the appropriate eCRF (eg, Prior/Concomitant Medications, Procedures and 
Non-Drug Therapy).  
Incyte Corporation  Page 67 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Assessment of Intensity  
The severi ty of AEs will be assessed using CTCAE v5.0 Grades 1 through 5.  If an event is not 
classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the 
grade of severity.  
The investigator will make an assessment of inten sity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment 
not indicated.  
• Grade 2:   Moderate; minimal, local, or noninvasive treatment indicated; limiting age -appropriate 
activities of daily living.  
• Grade 3:   Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_791504] d; disabling; limiting self -care activities of daily living.  
• Grade 4:   Life-threatening consequences; urgent treatment indicated.  
• Grade 5:   Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study cream  and e ach occurrence of 
each AE/SAE.  
• A "reasonable possibility " of a relationship conveys that there are medical facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use cl inical judgment to determine the possibility of a relationship.  
• The investigator will also consult the Reference Safety Information  in the  IB for study cream  in 
making his/her assessment.  
• Alternative causes, such as underlying or concurrent disease(s), con comitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study cream  administration, will be 
considered and investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed th e 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report.  However, the causality as sessment is one of the criteria 
used when determining regulatory reporting requirements.  Therefore, it is very important that 
the investigator always make an assessment of causality based on the available information 
for every event before the initial tra nsmission of the SAE.  
− The investigator may change his/her opi[INVESTIGATOR_9242] -up information and 
submit the updated causality assessment.  
Incyte Corporation  Page 68 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_89207]/or causality of the AE or SAE as fully as possible.  This may include additional laboratory tests 
or investigations, histopathological examinations, or consultation with other health care 
professionals.  
• Once an AE is detected, it should be followed in the AE eCRFs until it has resolved or until it is 
judged to be permanent; assessment should be made at each visit (or more frequently if necessary) of 
any changes in severity, the suspected relationship to the study cream , the interventions required to 
treat the event, and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg,  between visits), each 
change in severity will be reported as a separate AE.  
• If a participant dies during participation in the study or during a recognized follow -up period, the 
investigator will provide the sponsor with a copy of any postmortem findings,  including 
histopathology.  
• New or u pdated SAE information will be recorded in the originally completed eCRF  and reported to 
Incyte Pharmacovigilance (either via email/fax) until resolution, stabilization, the event is otherwise 
explained, or the participant  is lost to follow -up. 
• Any updated SAE data (including SAEs being downgraded to nonserious) will be submitted to the 
sponsor (or designee) within 24  hours of receipt of the information.  
9.4. Reporting of Serious Adverse Events  
All SAEs, regardless of suspected causality (eg, relationship to study cream  or study 
procedure[s]), occurring after the participant has signed the ICF/assent through [ADDRESS_1091365] be reported to the sponsor (or de signee) within 24 hours of 
learning of its occurrence, unless otherwise specified by [CONTACT_89191].  The investigator will 
submit any updated SAE data to the sponsor (or designee) within [ADDRESS_1091366] ively seek AE or SAE information after conclusion of study 
participation  (ie, after the safety follow -up visit or [ADDRESS_1091367] application of study 
cream ).  However, if the investigator learns of any SAE, including a death, at any time during 
this period, and after a participant has been discharged from the study, and he/she considers the 
event to be reasonably related to the study cream  or study participation, the investigator must 
notify the sponsor (or designee) within 24 hours of bec oming aware of the event.  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or t he participant is lost to f ollow -up (as defined in Section  7.3). 
Prompt notification by [CONTACT_11012] a SAE is essential so that l egal 
obligations and ethical responsibilities toward the safety of participants and the safety of a study 
cream  under clinical investigation are met.  
If the SAE is not documented in the Reference Safety Information of the  IB for the study cream  
(new occurrence) and is thought to be related to the study cream , the sponsor or its designee may 
urgently require further information from the investigator for reporting to health authorities.  The 
sponsor or its designee may need t o issue an Investigator Notification to inform all investigators 
Incyte Corporation  Page 69 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  involved in any study with the same drug that this SAE has been reported.  Suspected 
unexpected serious adverse reacti ons will be collected and reported to the competent authorities 
and relev ant ethics committees in accordance with Directive 2001/20/EC or as per national 
regulatory requirements in participating countries.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about th e safety of a study cream  under clinical investigation.  The sponsor 
will comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC, and investigators.  
Investigator safety reports must be prepare d for suspected unexpected serious adverse reactions 
according to local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg summary or listing of SAEs) from the sponsor will review and then file it 
along with the Investigator 's Brochure and will notify the IRB/IEC, if appropriate , according to 
local requirements.  
Serious Adverse Event Reporting  
• Information  about all SAEs is collected and recorded on the Adverse Event Form in the eCRF.  
• The investigator must report within 24 hours of learning of its occurrence any SAE via the EDC 
system (primary method) or by [CONTACT_791542] i n English  (only 
if the EDC system is not available) .  The contact [CONTACT_312370]/fax is listed in the Study Reference Manual or as per the Incyte Reference Guide for 
Completing the Serious Adverse Event Report Form.  
• In circumstances where the EDC system is not accessible for reporting SAE information (initial 
and/or follow -up SAE information) to the sponsor within [ADDRESS_1091368] be kept a t the study site (refer to the Incyte Reference Guide for 
Completing the Serious Adverse Report Form or Study Reference Manual for details and for the 
email address or fax number).  
• Follow -up information is also recorded in the eCRF and transmitted to Incyt e Pharmacovigilance via 
the EDC system.  The follow -up report should include information that was not provided previously, 
such as the outcome of the event, treatment provided, action taken with study cream  because of the 
SAE (eg, dose reduced, interrupted , or discontinued), or participant disposition (eg, continued or 
withdrew from study participation).  Each recurrence, complication, or progression of the original 
event should be reported as follow -up to that event, regardless of when it occurs.  
• Contacts for SAE reporting can be found in the Study Reference Manual.  
9.5. Emergency Unblinding of Treatment Assignment  
In a medical emergency during the study, if the investigator deems it necessary to determine 
optimal medical management of the participant , emergency unblinding will be performed 
exclusively by [CONTACT_458] [INVESTIGATOR_791505].   
The IRT system has an option to select for " Participant  Unblinding" in the event that a 
participant's  treatment needs to be unblinded in the case of a medical emergency.  The 
Incyte Corporation  Page 70 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  investigator/subinvestigator will proceed to either final confirmation o r cancellation of the 
subjecting  unblinding procedure.  After providing a final confirmation  to unblind the selected 
participant , the investigator/subinvestigator will proceed to enter their IRT password as a final 
security measure.  Once a valid passwor d has been entered for the user' s account, IRT will 
display the participant's  unblinded information to the user.  
If a participant 's treatment assignment is unblinded, the sponsor or its designee must be notified 
immediately by [CONTACT_352953] -up with an email.  
If an investigator, site personnel performing assessments, or participant is unblinded, the 
participant must be withdrawn from the study cream , unless there are ethical reasons to have the 
participant remain on the study cream .  In these cases, the investigator must obtain specific 
approval from the sponsor 's (or its designee 's) medical monitor for the participant to continue  in 
the study.  
9.6. Pregnancy  
Pregnancy, in and of itself, is not regarded as an AE unless there is suspi[INVESTIGATOR_501005] a contraceptive medication or method.  
When a pregnancy has been confirmed in a part icipant during maternal or paternal exposure to 
study cream , the following procedures should be followed in order to ensure safety:  
• The study cream  must be discontinued immediately (female participants only ). 
• The investigator must complete and submit the I ncyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Data on fetal outcome are collected for regulatory reporting and drug safety evaluation.  
Follow -up should be conducted for each pregnancy to d etermine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_89210]-baby [CONTACT_765].  Pre gnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211].  Pregnancy follow -up information should be 
recorded on the same form and should include an assessment of the possible causal relat ionship 
to the sponsor 's study cream  to any pregnancy outcome, as well as follow -up to the first well -
baby [CONTACT_89212], whichever is later.  Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Preg nancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event Report Form and submitted to the sponsor or its designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, co ngenital 
anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant 's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form.  
Incyte Corporation  Page [ADDRESS_1091369] complaints associated with other 
study material will be reported directly to the respective manufacturer.  
The investigator or his/her d esignee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact [CONTACT_147111].  Any AE associated with a product 
complai nt should be recorded as described in Section  9.3. 
If the investigator is asked to return the product for investigation, he/she will return a copy of  the 
product complaint communication with the product.  
Incyte Corporation  Page 72 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  10. STATISTICS  
10.1. Sample Size Determination  
Approximately 315 participants will be randomized 2:2:1 to ruxolitinib cream 1.5% BID, 
ruxolitinib cream 0.75% BID, or vehicle cream BID.  The sample size calculati on is based on the 
Fisher exact test for the primary efficacy endpoint.  Based on the results from the 2 pi[INVESTIGATOR_157037], INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304, the response rate of IGA -TS at Week 8 is 
assumed to be 51% and 47% for the active arms (1.5% BID and 0.75% BID, respectively) versus 
14% for placebo.  Using a [ADDRESS_1091370] >  95% power to 
detect a difference between each of the 2 active treatment groups versus vehicle.  In addition to 
providing  adequate power for efficacy variables, the sample size is determined to provide a large 
database for safety evaluations.  
10.2. Populations for Analysis  
Table  12 presents the populations for analysis.  
Table  12: Populations for Analysis  
Population  Description  
ITT The ITT population includes all randomized participants.  Treatment groups for this 
population will be defined according to the treatment assignment at randomization.  
PP The PP population includes randomized participants who are considered to be 
sufficiently compliant with the Protocol.   In general, the following are important 
protocol deviations that may sign ificantly affect the primary analysis : 
Missing data for the primary endpoint  
Overall application compliance less than 80% during the  VC period  
Participants with one or more such deviations will be excluded from the PP 
population.  In addition, important protocol deviations related to inclusion/exclusion 
criteria, discontin uation criteria, and use of prohibited concomitant medications will 
be reviewed.  Decisions as to whether any of these deviations warrant exclusion 
from the PP population will be made prior to unblinding.  
Safety  The safety evaluable population includes al l participants who applied study cream  
at least once .  Treatment groups for this population will be determined according to 
the actual treatment the participant received on Day 1.  
LTS evaluable  All analyses for the LTS period will be conducted with the LTS evaluable 
population, which includes all participants who applied study cream  at least once  
during the LTS period.  
 
  
 
 
. 

Incyte Corporation  Page 73 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993 CONFIDENTIAL  10.3. Level of Significance  
A graphical procedure with gatekeepi[INVESTIGATOR_791506] g strategy for the primary and key secondary 
analyses will be implemented.  The unde rlying procedure is derived using the methodolog y 
developed by [CONTACT_613130] (2009).  This method will guarantee a stron g contr ol of the family-wise 
error rate. 
In Step 1, 2 families of 4 elementary hypotheses tests at Week 8 are grouped according to 
treatment comparison between each ruxolitinib cream group and the vehicle crea m group, where 
•Family 1 (1.5% BID vs vehicle):
−H11:  proportion of participants who achieve IGA -TS
−H12:  proportion of participants with a ≥  4-grade improvement in Itch NRS score
over baseline
•Family 2 (0.75% BID vs vehicle):
−H21:  proportion of participants who achieve IGA -TS
−H22:  proportion of participants with a ≥  4-grade improvement in Itch NRS score
over baseline
Step 2 has 2 families  of 4 hypotheses tests : 
•Family 3  (1.5% BID vs vehicle an d 0.75% BID vs vehicle  on Day 7 Itch NRS ):
−H13:  proportion of participants with a ≥ 4 -grade improvement in Itch NRS score
over baseline  to Day 7 (Week 1)  between 1.5% BID and vehicle
−H23:  proportion of participants with a ≥ 4 -grade improvement in Itch NRS score
over baseline  to Day 7 (Week 1) between 0.75% BID and vehicle
•Family 4 (1.5% BID vs vehicle and 0.75% BID vs vehicle on Day 3  Itch NRS ):
−H14:  proportion of participants with a ≥ 4 -grade improvement in Itch NRS score
over baseline  to Day 3 between 1.5% BID and vehicle
−H24:  proportion of participants with a ≥ 4 -grade improvement in Itch NRS score
over baseline to Day 3 between 0.75% BID and vehicle
To control the overall Type I error rate, 2 -sided α = 0.05, the Bonferroni 's method will be used.  
In Step 1, within Family 1 and 2, the endpoints are tested in a fixed sequence at Bonferronized 
2-sided α  = 0.025 level.  The key secondary endpoint will be tested only if the associated primary
endpoint  is rejected.  For any treatment strength , if the 2 related null hypotheses can be rejected,
then the fixed sequence for the other treatment strength  can be conducted at the 2-sided α = 0.05
level.  If all null hypotheses in Family 1 and 2 are rejected, in Step  2, the endpoints in Family 3
(H13 and H2 3) will be tested using Bonferroni -Hochberg 's procedure with o verall 2 -sided
α = 0.05 level. If both hypotheses  in Family 3 are rejected, the endpoints in Family 4 (H14 and
H24) will be tested similarly using Bonferroni -Hochberg 's procedure with overall 2-sided
α = 0.05 level. The approach is visualized in Figure  9.
Incyte Corporation  Page 74 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Figure  9: Control of the Overall Type I Error Rat e 
Step 1:  
 
Step 2:  
 
10.4. Statistical Analyses  
The SAP will be developed and finalized before database lock and will describe the participant 
populations to be included in the analyses and procedures for accounting for missing, unused, 
and spurious data.  This  section is a summary of the planned statistical analyses of the primary 
and secondary endpoints.  

Incyte Corporation  Page 75 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  10.4.1.  Primary Analysis  
The primary analysis will be based on the ITT population.  The primary alternative hypothesis 
(superiority of each active ruxolitinib arm, 1. 5% BID or 0.75% BID, compared with vehicle) will 
be tested at a 2 -sided α = 0.025 level using logistic regression.  This model will include the 
treatment group (1.5% BID, 0.75% BID, and vehicle) and stratification factors (baseline IGA 
score and age).  Exact logistic regression ( Mehta and Patel 1995 ) will be used for all of the 
comparisons if any of the treatment strengths  have an expected cell count < 5. 
The difference in IGA -TS rates (ruxolitinib cream/vehicle) a t Week 8 will be computed.  The 
95% confidence interval for the difference will be computed based on a large -sample normal 
approximation with continuity correction.  All nonresponders during  the VC period, as well as all 
participants who discontinue study treatment  at any time before the timepoint of interest, or 
discontinue from the study for any reason, will be defined as nonresponders for the nonresponder 
imputation analysis.  Subgroup analysis by [CONTACT_393626] (eg, IGA  score , country , and 
age) will be performed.  Details will be provided in the SAP.   The following approaches may be 
performed for s ensitivity analyses : 
• Longitudinal logistic regression with repeated measures:  
To adjust for the dependence underlying the hierarchical multilevel data  structure 
(visit, participant, and site), a longitudinal logistic regression with repeated measures 
will be applied .  In the model,  visits are nested within participants, which are further 
nested within sites.  
The primary endpoint binary response of each participant at Week 2, Week 4, and 
Week 8 will be included as the dependent variable.  Treatment (1.5% BID, 0.75% 
BID, and vehicle BID), the randomization stratification factors (baseline IGA score 
and age), visit, and treatment by [CONTACT_791543] b e included as fixed effects.  
Site level intercept and participant nested in site level intercept will be included as 
random effects.  The within -participant and within -site errors will be modeled by [CONTACT_791544] -covariance matrix.  The Kenward -Roger approximation will be 
used to estimate denominator degrees of freedom for this model.  
• Multiple imputation:  
Multiple imputation with missing at random assumption will be used as an alternative 
method to handle missing data.  A fully conditional speci fication method 
(van Buuren  2007 ) that assumes the existence of a joint distribution for all variables 
will be used to impute  the IGA score.   A regression model including treatment group, 
stratification factors  (baseline IGA score and age ), and baseline and scheduled 
postbaseline scores up to Week [ADDRESS_1091371] the uncertainty around the true 
values.  The primary endpoint binary response will be derived  for each of the imputed 
dataset s, and t he logistic regression  described in Section  10.4.1  will be applied.  The 
results wil l then be combined for the inference using Rubin 's rule.  
Incyte Corporation  Page 76 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • Last observation carry forward:  
For the participants who are missing postbaseline assessments, the last observed 
nonmissing postbaseline value s will be used to fill in missing values at Week 8.  Then 
the proposed logistic regression described in Section  10.4.1  will be applied to the 
imputed dataset.  
• Tippi[INVESTIGATOR_18275]:  
A tippi[INVESTIGATOR_791507].  The missing primary endpoint binary response at Week [ADDRESS_1091372].  
10.4.2.  Secondary Analyses  
Secondary efficacy analyses will be condu cted on the ITT population.  If the primary objective is 
achieved, the statistical comparisons for key secondary endpoints will be tested with the 
procedures specified in Figure  9.   
The Itch NRS score for baseline will be determined by [CONTACT_113116] 7 daily NRS scores directly 
before Day 1 (Day –7 to Day –1).  The by-visit Itch NRS score for postbaseline visits will be 
determined by [CONTACT_113116] 7 daily N RS scores directly before the visit day.  If 4 or more daily 
scores are missing (out of the 7),  the Itch NRS score at the visit  will be set to missing.  The same 
nonresponder imputation method as specified in the primary analysis will be used to han dle 
missing Week  8 itch data , and t he logistic regression  described in Section  10.4.1  will be applied 
to compare each ruxolitinib cream group and the  vehicle cream group  for the key secondary 
endpoint of Itch NRS score  respon ses at Week 8.  
For the key secondary endpoints  of Itch NRS score  respon ses on Day 7 (Week 1)  and Day 3, a ll 
participants who are missing Day 7 and/or Day [ADDRESS_1091373] been imputed, the binary variable for the ≥ 4-point improvement in Itch 
NRS score  on Day [ADDRESS_1091374] a relationship to study cream  will be 
considered to be treatment -related AEs.  If the investigator does not specify the relationshi p of 
the AE to study cream , then the AE will be considered treatment -related.  The incidence of AEs 
and treatment -related AEs will be tabulated.  
The clinical laboratory data will be analyzed using summary statistics; no formal treatment group 
comparisons a re planned.  Laboratory test values outside the normal range will be assessed for 
severity based on the normal ranges for the clinical reference laboratory.  The incidence of 
abnormal laboratory values and shift tables relative to baseline will be tabulate d. 
Descriptive statistics and mean change from baseline will be determined for vital signs (blood 
pressure, pulse, respi[INVESTIGATOR_697], and body temperature) , height, and weight  at each assessment 
time.  
  
 
 
10.5. Interim Analysis  
No formal interim analysis is planned for this st udy; however, t he following analyses will be 
performed : 
• The primary analysis will occur after the primary database lock, when all participants 
have completed the VC period.  The sponsor will be unblinded after the primary 
database lock; however, investigators and participants will remain blinded to the 
individual study treatment assignment . 
• The final analysis will occur when all participants have completed or withdrawn from 
the study.  

Incyte Corporation  Page 78 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investi gator Responsibilities  
• The Protocol, Protocol Amendments , ICF /assent , IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_97277]/IEC and health authorities before the study  is initiated.  
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_89222], the 
policies and procedures established by [CONTACT_1201]/IEC, and institutional req uirements.  
• Any amendments to the Protocol will require  approval from  both health a uthorities 
and the IRB/IEC before implementation of changes made to the study design, except 
for changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC.  
− Notifying the I RB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures.  
− Providing oversight of the conduct of the study at the site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country -speci fic regulations.  
• Adhering to the Protocol as described in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by t he 
IRB/IEC.  Each investigator is responsible for enrolling participants who have met 
the specified eligibility criteria.  
• Retaining records in accordance with all local, national, and regulatory laws but for a 
minimum period of at least [ADDRESS_1091375] article for 
investigation to ensure the availability o f study documentation should it become 
necessary for the sponsor or a regulatory authority to review.  
− The investigator must not destroy any records associated with the study  during the 
retention period  without receiving approval from the sponsor.  The inve stigator 
must notify the sponsor or its designee in the event of accidental loss or 
destruction of any study records.  If the investigator leaves the institution where 
the study was conducted, the sponsor or its designee must be contact[CONTACT_791545].  
− All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retention reg ulations.  
The sponsor will retain the original eCRF data and audit trail.  
Incyte Corporation  Page 79 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  11.1.1.  Identification of the Coordinating Principal Investigator  
A coordinating principal investigator [INVESTIGATOR_312327].  As part of their respo nsibilities, the coordinating principal investigator [INVESTIGATOR_312328].  Agreement with the final CSR will be documented by [CONTACT_312374].  
11.2. Data Management  
Data management will be performed in a valid ated EDC system.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines for instructions on data entry in the 
eCRF.  The study monitor  will reference the Monitoring Plan in order to ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan 's requirements.  Other data outside the EDC system required in the study co nduct 
of the Protocol , such as documents or results transmitted to the sponsor via a central laboratory 
or specialized technical vendors and as designated by [CONTACT_456], will have their own data flow 
management plans, study charters, , as applicable.  
The sponsor (or designee) will be responsible for  the following : 
• Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monitors perform ongoing source data verification to confirm that 
data entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approv ed Protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
• Managing and reconciling the data generated and/or collected , including documents 
and results such as laboratory or imaging data analyzed centrally by a design ated 
vendor of the sponsor.  
The investigator will be responsible for  the following : 
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the delivery of, all other results, documents, data, k now-how, 
or formulas relating to the study to the sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data,  photographs, diary data) 
or as otherwise speci fied in the Protocol.  

Incyte Corporation  Page 80 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • Maintaining adequate and accurate source documents and trial records that include all 
pertinent observations on each of the site 's trial participants.  Source data should be 
attributable, legible, contemporaneous, original, accurate, and complete.  Changes to 
source data should be traceabl e, should not obscure the original entry, and should be 
explained if necessary (eg, via an audit trail).   Source data are , in general , all 
information in original records and certified copi[INVESTIGATOR_122567], observations, or other  activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained in source 
documents (original records or certified copi[INVESTIGATOR_014]).  
• Verifying that data entries are accurate and correct by [CONTACT_791546].  
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF, sent to a central vendor designated by [CONTACT_456], or as 
described in other study and data flow manuals.  
− Source documents provi de evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed and 
available at the investigator 's site.   Example s of source documents are original 
documents, data, and records (eg, hospi[INVESTIGATOR_1097] ; electronic hospi[INVESTIGATOR_1097] ; 
clinical and office charts ; labor atory notes ; memoranda ; participants ' diaries or 
evaluation checklists ; pharmacy dispensing records ; recorded data from 
automated instruments ; copi[INVESTIGATOR_193049] d after verification as 
being accurate copi[INVESTIGATOR_014] ; microfiches ; photographic negatives ; microfilm or  
magnetic media ; x-rays; participants ' files; and e-records/ records kept at the 
pharmacy, at the laboratories , and at medico -technical departments involved in 
the clinical trial).  
Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may need to request previous medical records or transfer records,  
depending on the study.  Current applicable medical records must be available.  
• Sending participants ' data, either as unique samples, copi[INVESTIGATOR_014], or photographs, to be 
evaluated centrally or analyzed centrally, or both, by a qualified vendor designated by 
[CONTACT_456].  
− As required by [CONTACT_537719]'s privacy 
policies, if any photographs of participants are to be taken, the photographs must 
be limited to the area of the face or the body that is strictly necessary and the 
photog raphs should be masked (ie, identifying features such as eyes, mouth, scars, 
tattoos, or unique markings or features should be either obscured with a black bar 
or digitally pi[INVESTIGATOR_791508]) by a specially designated photography vendor prior 
to sending the photographs to Incyte or any other third -party vendors for analysis 
or further processing.  
Incyte Corporation  Page 81 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • Permitting study -related monitoring, sponsor audits, IRB/IEC review, and re gulatory 
inspections by [CONTACT_89225].  
− Monitoring:  Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  Th e 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
− Auditing:  Qualified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate co mpliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  The 
investigator must allow the auditors to review original source records and study 
documentation for all participants.  
− Regulatory inspection:  Regulatory  authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational 
product.  The investigator and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting  the eCRFs and other 
study -related documents.  The investigator must immediately notify the sponsor 
when contact[CONTACT_147115].  
11.3. Data Quality Assurance  
The sponsor assumes accountability for actio ns delegated to other individuals (eg, contract 
research organizations). The sponsor or designee is responsible for the data management of this 
study, including quality checking of the data. Further, monitoring details describing strategy , 
including definition of study -critical data items and processes (eg, risk -based initiatives in 
operations and quality such as risk management and mitigation strategies and analytical risk -
based monitoring), methods, responsibilities, and requirements, including hand ling of 
noncompliance issues, Protocol deviations, and monitoring techniques (eg, central, remote, or 
on-site monitoring) are provided in the Clinical M onitoring Plan and Project Management Plan . 
Quality tolerance limits will be predefined in the Integrated Quality and Risk Management Plan  
to identify systematic issues that can impact participants ' safety, efficacy results and analysis, 
and/or reliability of study results. These predefined parameters will be monitored during the 
study and can be ad justed during the study upon data review. Important deviations from the 
quality tolerance limit s and remedial actions taken, including reporting to IRBs/ IECs and health 
authoritie s if appl icable, will be summarized in the CSR . 
11.4. Data Privacy and Confidential ity of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data protection laws 
and regulations .  The investigator and the sponsor or its designee are responsible for ensuring 
that personal information is handled in acc ordance with local data protection laws (including but 
not limited to  HIPAA  and GDPR ) as applicable , and the sponsor operates comprehensive data 
privacy and data security programs that are applicable to this study .  Appropriate notice, or 
notice and consen t (as may be required by [CONTACT_501053]),  for collection, use, 
Incyte Corporation  Page 82 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  disclosure , and/or transfer (if applicable) of personal information must be obtained  in accordance 
with local data protection laws .  Appropriate data protection terms that comply with applicable 
laws will be included in relevant study agreements.  
To ensure confidentiality of records and protect personal data, p articipant names will not be 
supplied to the sponsor or its designee .  Only  the participant number will be recorded in the 
eCRF; if the participant 's name [CONTACT_75502] (eg, laboratory report), it must be 
obliterated on the copy of the document to be supplied to the sponsor or its designee .  Study 
findings stored on a computer will be stored in accordance with appropriate technical and 
organizational measures as required by [CONTACT_89227] . 
In the event of a data breach involving participant data, the sponsor or its designee will follow 
the sponsor's inc ident response procedures. The precise definition of a data breach varies in 
accordance with applicable law but may generally be understood as a breach of security leading 
to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure  of, or access to, 
personal data. In accordance with its incident response procedures, the sponsor will assess the 
breach to consider its notification and remediation obligations under applicable law.  
11.5. Financial Disclosure  
Before study initiation, all clini cal investigators participating in clinical studies subject  to FDA 
Regulation Title 21 CFR Part 54 – Financial Disclosure by [CONTACT_6230] (ie, "covered 
studies ") are required to submit a completed Clinical Inv estigator Financial Disclosure F orm t hat 
sufficiently details any financial interests and arrangements that apply .  For the purpose of this 
regulation, "clinical investigator " is defined as any investigator or subinvestigator who is directly 
involved in the treatment or evaluation of research  participants, including the spouse and each 
dependent child of the clinical investigator or subinvestigator .  These requirements apply to both 
US and foreign clinical investigators conducting covered clinical studies.  
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Clinical Investigator Financial Disclosure Form .  During a covered clinical 
study, any changes to the financial information previously reported by a clinical investigator 
must be  reported to the sponsor or its designee .  At the conclusion of the covered clinical study, 
the clinical investigators will be reminded of their obligations .  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obliga ted to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes 
in their financial information for a period of 1 year after completion of the covered clinical study.  
11.6. Publication Policy  
By [CONTACT_791547], the investigator and their institution agree that the results of the 
study may be used by [CONTACT_456], Incyte Corporation (Incyte), for the purposes of national and 
international registration, publication, and information for medi cal and pharmaceutical 
professionals.  Study results will be published in accordance with applicable local and national 
regulations.  If necessary, the authorities will be notified of the investigator 's name, address, 
qualifications, and extent of involvem ent.  The terms regarding the publication of study results 
are contained in the agreement signed with the sponsor or its designee.  A signed agreement will 
be retained by [CONTACT_3552].  
Incyte Corporation  Page [ADDRESS_1091376] been colle cted and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of  a study site by [CONTACT_11004]:  
• Failure of the investigator to comply with the Protocol , the requirements of the 
IRB/IEC or local health authorities, the sponsor 's procedures, or GCP guidelines . 
• Inadequate r ecruitment of participants by [CONTACT_093] . 
• Discontinuation of further study treatment  development . 
Incyte Corporation  Page 84 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  12. REFERENCES  
Akdis CA, Adkis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and 
adults: European Academy of Allergology and Clinical Immunology/American Academy of 
Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 
2006;118:152 -169. 
Bissonnette  R, Papp KA, Poulin Y, et al. Topi[INVESTIGATOR_166509]: a phase IIa 
randomized trial. Br J Dermatol 2016;175:[ADDRESS_1091377] procedures. Stat Med  2009;28:586 -604. 
Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: a [ADDRESS_1091378]? J Allergy Clin 
Immunol 2018;142:1033 -1040.  
 
 
 
Clinical Trials Facilitation and Coordination Group . Recommendations related to contraception 
and pregnancy testing in clinical trials. 20 20. 
de la O-Escamilla NO, Sidbury R. Atopic dermatitis: update on pathogenesis and therapy. 
Pediatr Ann 2020;49:e140 -e146.  
Dupi[INVESTIGATOR_12460] (dupi[INVESTIGATOR_12458]) injection [prescribing information]. Regeneron Pharmaceuticals, Inc; 
June 2020.  
Eichenfield LF, Tom WL, Chamlin SL, et al.  Guidelines of care for the management of atopic 
dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 
2014;70:338 -351. 
Eucrisa (crisaborole ) ointment [prescribing information]. [COMPANY_007] Inc; April 2020.  
European Medicines Agency. Guidance on the Management of Clinical Trials During the 
COVID -19 (Coronavirus) Pandemic. 2020.  
Food  and Drug Administration. Draft  Guidance on Pi[INVESTIGATOR_031]. March 2012.  
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Vener eol Suppl 
(Stockh) 1980;92:[ADDRESS_1091379] Working Group. A population -based 
survey of eczema prevalence in the [LOCATION_002]. Dermatitis 2007;18:82 -91. 
Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allerge n exposure in adults: a 
population -based study. Clin Exp Allergy 2007;37:526 -535. 
Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of 
the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527 -1534.  
Hong CH, Joseph M, Kim VH, Lansang P, Lara -Corrales I. Approach to the assessment and 
management of pediatric patients with atopic dermatitis: a consensus document. Section II: 
comorbid disease in pediatric atopic dermatitis. J Cutan Med Surg 2019;23 (suppl):12S -18S. 

Incyte Corporation  Page 85 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. 
Front Immunol 2019;10:2342.  
Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME . Treatment of atopic dermatitis 
with ruxolitinib cream (JAK1/J AK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 
2020a;145:572 -582. 
Kim BS , Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Effects of ruxolitinib cream 
on pruritus and quality  of life in atopic dermatitis: r esults from a phase 2, randomi zed, 
dose-ranging, vehicle - and active -controlled study. J Am Acad Dermatol 2020 b;82:1305 -1313.  
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015;73:395 -399. 
 
 
Lyons  JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, 
and treatment. Immunol Allergy Clin North Am 2015;35:[ADDRESS_1091380] logistic regression: theory and examples. Stat Med 
1995;14:2143 - 2160.  
Napo litano M, Fabbrocini G, Cinelli E, Stingeni L, Patruno C. Profile of baricitinib and its 
potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging 
clinical evidence. J Asthma Allergy 2020;13:89 -94. 
Papp K , Szepi[INVESTIGATOR_791509], Kircik L, et al. Efficacy and safety of ruxolitinib cream for the 
treatment of atopic dermatitis: results from two pha se 3, randomized, double -blind stu dies.   
Presented at: 2nd Annual Revolutionizing Atopic Dermatitis Conference ; April 5, 2020; 
Chicago, IL . 
Pruritus Resources. Numerical Rating Scale (NRS). Accessed July 28, 2021. 
http://www.pruritussymposium.de/numericalratingscale.html  
Ramirez  FD, Chen S, Langan SM, et al. Assessment of sleep disturbances and exhaustion in 
mothers of children with atopic dermatitis. JAMA Dermatol 2019;155:556 -563. 
Rönmark EP, Ekerljung L, Lötvall J, et al. Eczema among adults: prevalence, risk factors and 
relation to airway diseases. Results from a large -scale population survey in Sweden. Br J 
Dermatol 2012;166:1301 -1308.  
Ruxolitinib Cream Investigator 's Brochure. Wilmington, DE: Incyte Corporation.  
Spergel JM. Epi[INVESTIGATOR_190057]. Immunol Allergy 
Clin North Am 2010;30:269 -280. 
van Buuren S. Multiple imputation of discrete and continuous data by [CONTACT_352958].  Stat Methods Med Res 2007;16:219 -242. 
van der Schans JV, Çiçek R, de Vries TW, Hak E, Hoekstra  PJ. Association of atopic diseases 
and attention -deficit/hyperactivity disorder: a systematic review and meta -analyses. Neurosci 
Biobehav Rev 2017;74:139 -148. 

Incyte Corporation  Page 86 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993 CONFIDENTIAL  Vinding GR, Zarchi K, Ibler KS, Miller IM, Ellervik C , Jemec GB. Is adult atopic eczema more 
common than we think? - A population-based study in Danish 
adults. Acta Derm Venereol 
2014;94:480-482. 
Yaghmaie P, Koudelka CW, Simpson EL. Me ntal health comorbidity in patients with atopic 
dermatitis. J Aller gy Clin Immunol 2013;131:428-433. 
Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on 
families: a review. Pediatr Dermatol 2019;36: 66-71. 
Incyte Corporation  Page 87 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S 
For female p articipants in the study:  
The following methods that can achieve a failure rate of < 1% per year when used consistently and correctly are 
considered as highly effective birth control methods:  
• Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of 
ovulationa 
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulationa 
− oral 
− injectable  
− implantableb 
• Intrauterine device (IUD)b 
• Intrauterine hormone -releasing system (IUS)b 
• Bilateral tubal occlusionb 
• Vasectomi zed partnerb,c 
• Sexual abstinenced 
Acceptable birth control methods that result in a failure rate of more than 1% per year include  the followinge: 
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary mode of 
action  
• Male or female condom with or without spermicidef 
• Cap, diaphragm , or sponge with spermicidef 
For male participants in the study:  
Male participants should use a condom during treatment through [ADDRESS_1091381] low user dependency.  
,c Vasectomized partner is a highly effective method provided of avoiding pregnancy that partner is the sole sexual partner of t he 
study participant and that the vasectomized partner has received medical assessment of the surgical success.  
d In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as refraining from  
heterosexual intercourse during  the entire period of risk associated with the study treatments.  The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of t he 
participant.  
e Choices are for US and Canada participants only and include above <  1% failure rate methods . 
f A combination of male condom with either cap, diaphragm or s ponge with spermicide (double barrier methods) are also 
considered acceptable, but not highly effective, birth control methods.  
Source:  Clinical Trials Facilitation and Coordination Group [ADDRESS_1091382] of ongoing 
clinical trials.  In line with the FDA and European Medicines Agency 's Guidance on the 
Management of Clinical Trials During the COVID -19 (Coronavirus) Pandemic ( 2020 ), the 
following Protocol considerations are provided to ensure participant safety is maintained and 
adequate benefit/risk analyses are applied relative to the completion of study procedures and 
maintaining the investigational pro duct supply chain.  
Recognizing the flexibility required to manage the impact of the pandemic on this clinical trial, 
additional details will be added to respective study reference manuals  and project plan 
documents and communicated to the investigative sit es as needed.   For any additional questions, 
please confer with the medical monitor.  
Number of Study Participants  
The evolving situation of the pandemic may result in a substantial number of participants  
droppi[INVESTIGATOR_791510] , which could affect the data integrity of the trial.  Because of this 
risk, the sponsor may decide to recruit additional participants in the study, beyond the expected 
number, to mitigate such risk.  
Study Visits  
There are a number of on -site visits that would be required to e nsure study validity.  If there are 
local travel restrictions  or isolation requirements, or the investigator determines it to be unsafe 
for participants to attend the scheduled study visit, the site staff may conduct certain  visits via 
telemedicine (phone or video calls) to minimize participant risk as follows : 
• VC period  
− The following vis its must be performed in person : 
o Screening  
o Day 1 (Baseline)  – if baseline visit cannot be performed on -site within the 
screening period of 28 (+ 7) days, the participant  will be considered to have 
failed screening.  Participants who fail screen ing due to COVID -19 may be 
rescreened (see Section  5.4) at a later time, i f feasible.  
o Week 8/E T (with a window of ± 7 days)  
− The following visits may be conducted via telemedicine , if necessary:  
o Week 2  
o Week 4  
• LTS period  
− The following visit s should be in person  whenever possible : 
o Week 24  ( ± 7 days)  
o Week 52/EOT /ET (± 10 days)  
− Other visits during the LTS period may be conducted via telemedicine  if 
necessary.  
Incyte Corporation  Page 91 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • Telemedicine visits  
− At a minimum, a review of AEs, concomitant medications, and study cream  
application compliance must be completed and recorded in the EDC.  
− No efficacy assessments can be performed even if the telemedicine visit is a video 
call or photography of the active lesion is provided.  Note:  The presence or 
absence of active AD lesions may be verified through a video call, if available.  
− Participants  should continue to complete  the daily Itch NRS,  
 in 
their diary if the visit affected is during the VC  period .  If the participant is in the 
LTS period of the study,  the start and end dates of treatment cycles must be 
recorded.  
− All assessments not performed will be recorded in the EDC as protocol deviations 
and reason documented as COVID -19. 
Investigational Medicinal Product Dispensing and Distribution  
In order to ens ure the continuity of providing participants  with clinical supplies , should they not 
be able to attend an onsite study visit,  within the constraints imposed by [CONTACT_47098],  the site 
staff may decide to supply study treatment  to participant s as follows:  
• Adequate supplies of study cream  can be shipped to the participant by [CONTACT_791548] a third -party service with approval from the participant.  The third -party vendor 
will be agreed upon with the sponsor.  
• The participant may request, with prior arrang ement/agreement with the site, an 
authorized individual (a relative or delegate) to retrieve the study cream  from the 
study site if the participant is unable to personally to do so.  
Clinical Trial Monitoring  
Study monitoring visits may be postponed ; howeve r, the site monitor will continue to employ 
off-site monitoring practices such as routine communication methods (eg, phone calls, emails, 
video visits) with the sites to get information on trial progress, participant status, and issue 
resolution as detaile d in the Data Monitoring Guidelines, Re mote source data verification.  
If the study site monitor cannot be on -site to perform  the final drug accountability for 
reconciliation purposes, and the operation cannot be postponed, it may be performed  by a 
pharmaci st from the hospi[INVESTIGATOR_312332]/data manager with suitable 
training.  The study cream  can be returned to the sponsor by [CONTACT_5035][INVESTIGATOR_791511], if applicable, and with sponsor approval.  

Incyte Corporation  Page [ADDRESS_1091383] Parties/Specialized Service Companies  
If necessary, direct contracts can be established with third -party local physicians to conduct 
activities related to the clinical management of participants for whom the in vestigator is 
responsible and maintains oversight.  In such situations, the investigator is required to provide 
the local physician with a delegation letter listing all delegated activities.  The sponsor, through 
the study investigator or institution, will  reimburse the local physician for the test/procedures 
conducted outside of the standard of care.  
Reimbursement of Extraordinary Expenses  
The sponsor will arrange to reimburse the participant (participant 's parent [s]/legal guardian) for 
any extraordinary e xpenses  for AEs that are related to study cream , keepi[INVESTIGATOR_791512] (eg, travel expenses for the local laboratory visit [s], the costs of local 
[proximate] laboratory tests).  
Incyte Corporation  Page 93 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  APPENDIX  D. BODY SURFACE AREA CA LCULATION GUIDES  
1. Handprint Method ( use of participant's hand)  
 
2. BSA Calculation Guides  
a) BSA for Children ≥ 3 and < 11 Years of Age  
 
 
 
 
 
 
0.1% BSA  ▪ 1% BSA = the palm plus 5 digits, with 
fingers tucked together and thumb 
tucked to th e side (handprint)  
▪ Thumb as 0.1% BSA.  

Incyte Corporation  Page 94 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  b) BSA for Infants ≥ 3 Months and < 3 Years of Age  
 
 

Incyte Corporation  Page 95 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  APPENDIX  E. ECZEMA AREA AND SEVE RITY INDEX  
The EASI score examines 4 areas of the body and weights them as follows:  
• Subjects 8 years of age and older:  
− Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower 
limbs  (LL) = 0.4. 
• Subjects 0 to 7 years of age:  
− Head/Neck (H) = 0.2, Upper limbs (UL) = 0. 2, Trunk (T) = 0. 3, and Lower limbs 
(LL)  = 0.3. 
The percentage of area involved for each of the 4 body regions is weighted as follows:  0 = no 
eruption, 1  = some to < 10%, 2  = 10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5  = 70% to 
89%, and 6 = 90% to 100%.  
Each of the 4 body regions is assessed separately f or erythema (E), induration/papulation/edema 
(I), excoriations (Ex), and lichenification (L) for an average degree of severity of each sign in 
each region with:  0 = none, 1 = mild, 2 = moderate, and 3= severe, with half -step allowed.  
 
Incyte Corporation  Page 96 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  EASI Score Calculation Tool for 8 Years of Age and Older  
Body Region  Erythema  
(0-3) Edema/  
Papulation  
(0-3) Excoriation  
(0-3) Lichenification  
(0-3) Region 
Score  
(0-6) Multiplier  Score per Body 
Region  
Head/n eck (               + + +                                 ) X X 0.1   
Trunk  (               + + +                                 ) X X 0.3   
Upper limbs  (               + + +                                 ) X X 0.2   
Lower limbs  (               + + +                                 ) X X 0.4   
The final EASI score is the sum of the 4 region scores:   
____________  
   (0-72) 
EASI Score Calculation Tool for 0 to 7 Years of Age  
Body Region  Erythema  
(0-3) Edema/  
Papulation  
(0-3) Excoriation  
(0-3) Lichenification  
(0-3) Region 
Score  
(0-6) Multiplier  Score per Body 
Region  
Head/ neck (       + + +                    ) X X 0.2   
Trunk  (       + + +                    ) X X 0.3   
Upper limbs  (       + + +                    ) X X 0.2   
Lower limbs  (       + + +                    ) X X 0.3   
The final EASI score is the sum of the 4 region scores:   
____________  
   (0-72) 
 
Incyte Corporation  Page 97 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  APPENDIX  F. PROTOCOL AMENDMENT S UMMARY OF CHANGES  
Document  Date  
Amendment 1  06 MAY  2021  
Amendment 2  02 AUG  2021  
Amendment 3  19 AUG  2021  
Amendment 4  06 APR  2022  
Amendment 5  29 JUL 2022  
Amendment 6  22 FEB 2023  
Amendment 6 (22 FEB 2023 ) 
Overall Rationale for the Amendment:  
The primary purpose of the amendment is to add 2 key secondary endpoints .  Details of these 
and other minor changes  are listed below.  
1. Section 1, Protocol Summary (Table 1:  Primary and Key Secondary Objectives and 
Endpoints); Section 3, Objectives and Endp oints (Table 7:  Objectives and 
Endpoints); Section 10.3, Level of Significance; Section 10.4.2, Secondary Analys es 
Description of change:   The proportion of participants with a ≥  4-point improvement in 
Itch NRS score from baseline to Day 7 (Week 1) and from baseline to Day 3 were added 
as key secondary endpoints.  Statistical details were also added for these 2 additional key 
secondary endpoints.  
Rationale for change:   To include an alpha -controlled assessment of early itch reduction 
with ruxolitinib cre am.  
2. Section 1, Protocol Summary (Table 2:  Key Study Design Elements)  
Description of change:   , MD, was added as the coordinating principal 
investigator . 
Rationale for change:   A coordinating principal investigator  [CONTACT_60296] . 
3. Section 10.2, Populations for  Analysis  
Description of change:   Overall application compliance, which is an example  of 
important protocol deviations that may significantly affect the primary analysis as part of 
the definition of the PP population , was modified from less than 6 0% to less than 8 0%. 
Rationale for change:    
4. Incorporation of administrative changes.   Other regulatory guidance and  
administrative changes have been incorporated throughout the Protocol and are noted in 
the redline version of the amendment.  

Incyte Corporation  Page 98 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Amendment 5 ( 29 JUL 2022)  
Overall Rationale for the Amendment:  
The primary purpose of the amendment is to increase the  overall sam ple size .  The changes have 
no safety implications for this population of participants.  Details of these and other minor 
changes  are listed below.  
1. Section 1, Protocol Summary (Table 2:  Key Study Design Elements ; 
Figure  1:  Study Design Schema ); Section 1 0.1, Sample Size Determination  
Description of change:   The sample size for this trial is being increased from 250 to 
315 participants.  
Rationale for change:   The evaluable population for the key secondary endpoint 
(proportion of participants with a ≥ 4-point improvement in Itch NRS score from baseline 
to Week 8 ) requires participants [ADDRESS_1091384] 180 participants are required i n this subgroup, and to achieve that the overall 
population will  be increased from 250 to 315.  
The sample size calculation of 180 in this subgroup is based on the results from the 
2 pi[INVESTIGATOR_36491], INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304, in which the response rate for 
the key secondary endpoint at We ek 8 is assumed to be 52% and 42 % for the active arms 
(ruxolitinib 1.5% cream BID and ruxolitinib 0.75% cream BID, respectively) versus 16 % 
for vehicle cream BID .  Using a [ADDRESS_1091385] >  90% 
power to detect a difference between ruxolitinib 1.5% cream BID versus vehicle cream 
BID and 7 0% power to detect a difference  between  ruxolitinib 0.75% cream BID versus 
vehicle cream.  In addition to providing adequate power for all efficacy v ariables, the 
sample size increase is also providing  a large r database for safety evaluation.  
2. Section 1, Protocol Summary (Table 3:  Schedule of Activities:  Vehicle -Controlled 
Period); Section 5.1, Inclusion Criteria  (Inclusion Criterion 8) ; Section 8.2. 3, Target 
Lesion Identification ; Section 8.2.4, Photography  
Description of change:   Instructions were added such that only participants who are 
participating in photography are required to identify and measure target lesions at the 
screening and baseline visits . For participants not participating in photography, the 
identification and measurement of target lesions are optional.  
Rationale for change:   Clarification was added that only participants who are 
participating in photography are required to identif y and measure targe t lesions .  
Incyte Corporation  Page 99 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  3. Section 5.1, Inclusion Criteria  (Inclusion Criterion 6) ; Section 8. 2.7, Itch Numerical 
Rating Scale  
Description of change:   Instructions were added such that participants who are aged 
6 years to <  [ADDRESS_1091386] 4 of the 7 days  immediately 
prior to the Day  1/baseline , Week 2, Week 4, and Week 8 visits. 
Rationale for change:   Clarification added in order to adequately calculate average 
baseline and weekly Itch NRS scores . 
4. Section 9.4, Reporting of Serious Adverse Events  
Description of change:   Removed the last study visit as a possible last timepoint for 
reporting SAEs so that all SAEs are reported through [ADDRESS_1091387] application of 
study cream . 
Rationale for change:   Changed  in order to align with other sections for AE/SAE 
reporting timelines . 
5. Incorporation of administrative changes.   Other regulatory guidance and  
administrative changes have been incorporated throughout the Protocol and are noted in 
the redline version of the amendment.  
Incyte Corporation  Page 100 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Amendment 4 (06 APR  2022)  
Overall Rationale for the Amendment:  
The primary purpose of the amendment is to .  These changes have no 
safety implications for this population of participants.  Details of these and other minor changes  
are listed below.  
1. Section 1, Protocol Summary  (Table 1:  Primary and Key Secondary Objectives and 
Endpoint) ; Section 3, Objectives and Endpoints (Table 7 :  Objectives and 
Endpoints ); Section 10.3, Level of Significance; Section 10.4, Primary Analysis  
Description of change:   The endpoint of the proportion of participants who achieve 
EASI75 at Week [ADDRESS_1091388] been modified accordingly.  Further, t he 
gatekeepi[INVESTIGATOR_791513] t he primary and key secondary 
endpoints are both tested for the 1.5% ruxolitinib cream strength before testing for the 
0.75% strength . 
Rationale for change:   . 
2. Section 1, Protocol Summary (Table 3:  Schedule of Activities:   Vehicle -Controlle d 
Period)  
Description of change:   Exceptions for dispensing and applying the study cream  at site 
visits were updated to include  Week 8 if the IGA score is 0.  
Rationale for change:   Clarification that at the Week 8 visit, if the IGA score is 0, no 
study cre am should be applied.  
3. Section 1, Protocol Summary ( Table 3:  Schedule of Activities:  Vehicle -Controlled 
Period) ; Section 5.4, Screen Failures; Section 8.1.1, Informed Consent Process; 
Section 8.1.2, Screening Procedures  
Description of change:   Participants on prior medications requiring a [ADDRESS_1091389] reconsent if rescreened ≥ 35 days 
after the initial screening.  
Rationale for change:   To clarify that the 35 -day screening window pertains to  the 
4-week washout period noted in Exclusion Criterion 5b . 
4. Section 1, Protocol Summary (Table 4:  Schedule of Activities:  Long -Term Safety 
Period)  
Description of change:   Added clarification that  application of study cream  at site  visits  
only pertains to participants with active AD lesions at the time of visit.  
Rationale for change:   Clarification to be consistent with Section 6.1.  

Incyte Corporation  Page 101 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  5. Section 1, Protocol Summary (Table 4:  Schedule of Activities:  Long -Term Safety 
Period) ; Section 8 .9.1, Safety Follow -Up 
Description of change:   Clarified that participants who are in an observation/no 
treatment cycle from the Week 48 visit or earlier until the Week 52/EOT visit can 
complete the safety follow -up and Week 52/EOT visits at the same time.  
Rationale for change:   For consistency  with changes previously made to Section 4.1.  
  
 
. 
  . 
7. Section 4.1, Overall Design  
Description of change:   Removed t he option for the investigator (in consultation with 
the medical monitor) to determine if a participant experiencing a lack of efficacy aft er 
8 weeks of continuous treatment in the LTS period should be discontinued, to match the 
language in Section 7.1.1.  
Rationale for change:   . 
8. Section 5.2, Exclusion Criteria  
Description of change:   Exclusion Criterion 6c has been modified t o clarify that 
COVID -19 vaccination is allowed before the baseline visit . 
Rationale for change:   Clarification.  
9. Section 5.2, Exclusion Criteria  
Description of change:  Exclusion Criterion 6d has been modified to note that the 
frequency of "bleach" baths must remain the same throughout the study.  
Rationale for change:  Consistency with Section 6.6.2 . 
10. Section 5.2, Exclusion Criteria;  
 
Description of change:   Exclusion Criterion 11, which exclude d participants with  
inadequate venous access in nonlesional areas for laboratory blood draws, has been 
removed .  
 
 
Rationale for change:    
 
 
 
 
 
 
 

Incyte Corporation  Page 102 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  11. Section 6.1, Study Treatment s Administered  
Description of change:   Further instructions have been added regarding approval to treat 
additional areas of AD with study cream . 
Rationale for change:   Providing additional guidance.  
12. Section 6.5, Dose Modifications  
Description of change:   Clarification has been provided to the dose -modi fication rules . 
Rationale for change:   Providing additional guidance.  
13. Section 6.5.1, Criteria and Procedures for Application Interruptions and 
Adjustments of Study Cream  
Description of change:   Added caution that p articipants should be closely monitored fo r 
the development of signs and symptoms of infection and added instructions for study 
cream  interruption in case of infection.  
Rationale for change:   Added for consistency with current US labeling . 
14. Section 6.6.2, Restricted Medications and Procedures  
Description of change:   Clarification has been provided to indicate that  the use of 
allergen immunotherapy is allowed if the participant is on a stable dose at baseline and 
continues at the same dose.  
Rationale for change:   Previously, allergen immunothera py was not recommended, but 
the sponsor felt that it should be allowed throughout the study if a stable dose.  
15. Section 6.6.2, Restricted Medications and Procedures; Section 6.6.3, Prohibited 
Medications and Procedures  
Description of change:   The use of systemic corticosteroids  is no longer completely 
prohibited. Short -term use in response to an AE for participants in the LTS period is now 
allowed, and the decision to keep the participant in the study (or early termination) will 
be made in co nsultation with the medical monitor . 
Rationale for change:   The sponsor believes  that the short -term use of systemic 
cortico steroids will not  impact assessment of the long-term safety  of ruxolitinib cream  
16. Section 8.2.7, Itch Numerical Rating Scale  
Descript ion of change:   The definition  for baseline itch  has been updated to state that the 
average must include  Itch NRS values for at least 4 of the 7 days.  
Rationale for change:   The sponsor believes that having Itch NRS values for at least 4 of 
the 7 days dire ctly before  baseline is an appropriate minimum for the calculation of the 
average baseline Itch NRS score for assessment of Inclusion Criterion 6.  
Incyte Corporation  Page 103 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  17. Section 8.4.3 , Vital Signs, Height, and Weight  
Description of change:   It was clarified that at each visit in which the participant's height 
is measured, it is the average of 3 measurements that should be entered in the EDC  rather 
than each of the 3 measurements . 
Rationale for change:   Previously , it was implied that all 3 measurements at a given visit 
should b e recorded, whereas only 1 value (the average) is required . 
18. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  
Incyte Corporation  Page 104 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Amendment 3 (19 AUG  2021)  
Overall Rationale for the Amendment:  
The primary purpose of the amendment is to  concerning  Amendment 1.   
These changes have no safety implications for this population of participants.  Details of these 
and other minor changes  are listed below.  
1. Section 1, Protocol Summary  (Table 2:  Key Study Design Elements) ; Section 4.1 , 
Overall Design  
Description of change:   Added d etails of the countries where the study will be 
conducted as well as the number of sites . 
Rationale for change:  . 
2. Section 4.1, Overall Design  
Description of change:   Clarified  that participants who are in an observation/no 
treatment cycle  from the Week 48 visit or earlier until the Week 52/EOT visit can 
complete the safety follow -up and Week 52/EOT visits at the same time . 
Rationale for change:  The intent of the safety follow -up visit is to assess participants at 
least [ADDRESS_1091390] application of study treatment; for participants who do  not 
apply study treatment from the Week [ADDRESS_1091391] due to having no active AD lesions , 
the Week 52/EOT visit would occur at approximately [ADDRESS_1091392] 
application of study treatment .  Hence, it is appropriate to combine the Week 52/EOT and 
safety fo llow-up visits  for these participants . 
3. Section 5.2, Exclusion Criteria  
Description of change:   Exclusion Criterion [ADDRESS_1091393] results had to be clinically significant.  This is not the case, 
so "clinically significant laboratory results" has been replaced with "clinical laboratory 
test results ," which was the language used in Amendment 1 . 
Rationale for change:  A change made in Amendment 2 was deemed inappropriate, and 
the text reverted to that us ed in Amendment 1 . 
4. Section 6.1 , Study Treatments Administered  
Description of change:   For p articipants whose total areas of AD to be treated exceed 
20% BSA  in either the VC period or LTS period, the option to treat these additional areas 
has been removed, and instructions have been added that these participants  should be 
discontinued from study treatment.  
Rationale for change:  The intent was only to allow p articipants  to treat areas of AD up 
to a maximum of 20% BSA in this study, so the 2 instances that suggested otherwise 
needed to be corrected . 

Incyte Corporation  Page 105 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  5. Section 7.1.1 , Reasons for Discontinuation  
Description of change:   Added a  reason for discontinuation :  if the extent of AD to be 
treated (ie. any body part excluding the scalp) exceed s 20% BSA  during either the VC 
period or the LTS period . 
Rationale for change:  Participants are only allowed to treat areas of AD up to a  
maximum of 20% BSA  in this study, so it has be en made clear that if the extent of AD 
exceeds 20% BSA , a participant must be discontinued  from study treatment . 
6. Section 10.2 , Populations for Analysis  (Table 12:  Populations for Analysis)  
Description of change:   Added e xamples of protocol deviations that would exclude 
participants from the PP population.  
Rationale for change:  . 
7. Section 10.4.1, Primary Analysis  
Description of change:   Added f ull details of the planned sensitivity analyses  for the 
handling  of missing data and the tippi[INVESTIGATOR_18275] . 
Rationale for change:  . 
8. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of t he 
amendment.  

Incyte Corporation  Page 106 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Amendment 2 ( 02 AUG  2021)  
Overall Rationale for the Amendment:  
The primary purpose of the amendment is to revise Exclusion  Criteri on 3, which is over ly 
restrictive , to create consistency across the AD program and for ease of recruitment, minimizing  
screen failures for nonsignificant clinical laboratory  results.  These changes have no safety 
implications for this population of participants.  Additional changes  are listed below.  
1. Protocol Summary (Table 3:  Schedule of Activities: Vehicle -Controlled Period ; 
Table 4:  Schedule of Activities:  Long -Term Safety Period ) 
Description of change:   Added guidance to study drug application during site visits  
during the VC period ; clarified BSA and IGA assessments and range s at the Week 8 visit;  
deleted Day 1/baseline compliance check;   
 
; added recommendation on use of a topi[INVESTIGATOR_713903]; 
and specif ied serologic testing for HIV at screening.  
Rationale for change:  To provide additional guidance for clarity  and correct an 
administrative error  (Day 1/baseline compliance check) . 
2. Protocol Summary (Table 3:  Schedule of Activities: Vehicle -Controlled Period ); 
Section  5.2, Exclusion Criteria (Exclusion Criterion 6) ; Section 6.1, Study 
Treatments Administered; Section 61.1, Study Treatment Application Guidance; 
Section 6.5, Dose Modifications; Section 6.5.1, Criteria and Procedures for 
Application Interr uptions and Adjustments of Study Drug;  
; 
Section  [IP_ADDRESS], Pregnancy Testing  
Description of change:  
• Protocol Summary and Section [IP_ADDRESS]:  Clarified that Day 1  pregnancy testing will 
be performed only if the interval between screening and Day 1 is > 2 weeks.  
• Section 5.2:  Changed  inactivated vaccines and live vaccines to live -attenuated 
vaccines and added topi[INVESTIGATOR_537679] s to the 1 -week washout period before  baseline . 
• Section 6.1:  Added allowance for study drug applications to be approximately 
8 hours apart.  
• Section 6.1.1:  Updated application instructions to use a fingertip to apply study drug 
in small amounts.  
• Section 6.5 and Section 6.5.1:  Added text tha t changes in frequency of application 
are not allowed and that treatment may be temporarily withheld at a lesional site but 
may be continued elsewhere and must be recorded as a dose interruption in the AE 
eCRF page.  
  
 
Rationale for change:  To provide additional guidance for clarity.  

Incyte Corporation  Page 107 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  3. Section  5.2, Exclusion Criteria (Exclusion Criteri a 2 and 3) 
Description of change:  Added "day" to 880  µg (880 µg/day)  to Exclusion Criterion 2g; 
moved the criterion regarding medical history of hepatitis B virus or hepatitis C virus 
from Exclusion Criterion 4 to Exclusion Criterion 2i; r evised  Exclusion Cri terion [ADDRESS_1091394] resul ts at screening; deleted Exclusion 
Criteri on 3a (any value <  0.75 × LLN [other than bilirubin ]); moved Exclusion Criterion 
3b to Exclusion Criterion 3 d and revised " any value > 2.5 × U LN" to "AST or ALT 
≥ 2.5 × ULN "; added Exclusion C riterion 3 d heading "liver function tests "; revised 
Exclusion Criterion 3 e to change the estimated GFR from < 15 to < 30 mL/min/1.73 m2; 
added Exclusion Criteria 3c and 3g regarding cytopenias at screening and any other 
clinically significant laboratory result that, in the opin ion of the investigator, poses a 
significant risk to the participant, respectively ; and moved Exclusion Criterion 9 
regarding serologic testing for HIV to Exclusion Criterion 3f. 
Rationale for change:   Exclusion Criteria 2 were revised for update s and clarification ; 
Exclusion Criteria 3 were revised, added, or moved to be consistent with exclusion 
criteria from other AD protocols.  In addition, o riginal Exclusion Criteria 3a and 3b were 
overly restrictive ; Exclusion Criterion 3d  was revised to group the [ADDRESS_1091395] s 
for clarity;  and Exclusion Criterion 3e, per recommendation by [CONTACT_791549] , was revised to provide a more conservative estimated GFR value.  
4. Section 6.5.1, Criteria and Procedures for Application Interruptions and 
Adjustments of Study Drug (Table 9:  Guidelines for Interruption and Restar ting of 
Treatment Applications i f Adverse Event Is Deemed Related to the Study Drug)  
Description of change:  Deleted ALT and AST (> 3 × ULN) , revised ANC to < 750/μL 
(without fever)  and < 1000/ μL (with fever),  and updated AST or ALT ( from > 5 to >  20 
× ULN).  
Rationale for change:  To provide a more succinct guideline because  ALT and AST 
> 3 × ULN is covered by "any other G rade 3 or higher laboratory abnormality " 
assessment , to define ANC levels with fever or without fever , and to update  AST or ALT 
to > 20 × ULN to be consistent with CTCAE v5.0 grading.  
5. Section 6.6.2,  Restricted Medications and Procedures ; Section 6.6.3, Prohibited 
Medications and Procedures  
Description of cha nge:  Moved  allergen immunotherapy and live -attenuated 
vaccination s from prohibited medication s to restricted medication s. 
Rationale for change:  Allergen immunotherapy and immunizations with a 
live-attenuated vaccin e are standard of care for this pediatri c population and therefore 
may be allowed during the VC period should the investigator deem it necessary.  
Incyte Corporation  Page 108 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  6. Appendix C, COVID -19 Pandemic Mitigation Strategies and Instructions (Study 
Visits)  
Description of change:   
 
Rationale for change:  Administrative error . 
7. Incorporation of administrative changes.   Other minor, administrative changes have  
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  

Incyte Corporation  Page 109 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  Amendment 1 (06 MAY  2021 ) 
Overall Rationale for the Amendment:  
The primary purpose of the amendment is to incorporate revision s request ed by [CONTACT_791550] .  Additional changes are 
summarized below.  
1. Protocol Summary (Table 3:  Schedule of Activities:  Vehicle -Controlled Period; 
Table 4:  Schedule of Activities:  Long -Term Safety Period); Section [IP_ADDRESS], 
Demographics and General Medical History; Section 8.4.3, Vital Signs, Height, and 
Weight  
Description of change:   Added guidance to capture height and weight of not only each 
participant, but also both parents of each participant  (if available) , and to record these 
data in the EDC.  
Rationale for change:   To provide clarity that the growth measurements will be entered 
into the EDC and evaluated at the end of the study.  
  
 
 
 
 
   
 
   
 
 
3. Section 2, Introduction  
Description of change:   Revised the order of the sections for clarity  and added text . 
• Moved Section 2.2, Study Rationale , to Section 2.3 . 
• Moved Section 2.2.1 , Scientific Rationale for Study  Design , to Section 2.3.1 . 
• Moved Section 2.2.2 , Justification for the Selected Treatment Regimen , to Section 
2.3.2 . 
• Moved Section [IP_ADDRESS], INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304, to Section 2.2.1  and 
changed the heading to  INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304:  Phase 3 
Adole scent/Adult Studies . 
• Moved Section [IP_ADDRESS], INCB [ZIP_CODE] -102:  Pharmacokinetic Pediatric Study , to 
Section 2 .2.2. 
• Created Section 2.2 , Pi[INVESTIGATOR_9205] 3 Studies and Pi[INVESTIGATOR_791478] , for Section 
2.2.1 , INCB [ZIP_CODE] -303 and INCB [ZIP_CODE] -304:  Phase 3 Adolescent/Adult Studies , 
and Section 2.2.2 , INCB [ZIP_CODE] -102:  Pharmacokinetic Pediatric Study . 

Incyte Corporation  Page 110 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  • Moved Section [IP_ADDRESS] , INCB [ZIP_CODE] -206, to part of Section 2.3.2, Justification for the 
Selected Treatment Regimen , and a dded text to provide further  information for the 
justification of the selected treatment regimen.  
Rationale for change:   Administrative corrections . 
4. Section 5.2, Exclusion Criteria  (Criteria 2 h, 3b, and 3d) 
Description of change:  
• Exclusion Criterion 2h:  Added a criterion to exclude participants who are on 
maintenance dialysis . 
• Exclusion Criterion 3b:  Added text to clarify that the laboratory test criterion for the 
ULN does not include for serum creatinine levels.  
• Exclusion Criterion 3d:  Added a c linical laboratory test  criteri on for the lower limit 
of the estimated GFR . 
Rationale for change:   To address Canad ian Health Authorit y request . 
5. Section 5.2, Exclusion Criteria (Criteria 6c)  
Description of change:   Clarified the requirement for inactivated vaccines.  
Rationale for change:   To simplify the immunization requirement.  
6. Section 6.1, Study Treatments Administered; Section 6.1.1 , Study Treatment 
Application Guidance  
Description of change:  Deleted text regarding redispensing of study drug, r eplaced 
Figure 8 (Fingertip Unit of  a Cream ), and deleted the study drug application instructions . 
Rationale for change:  To simplify the study drug dispensing process , to provide a better 
representation of the cream , and to avoid overlap of information that will be include d in 
the Study Manual . 
7. Section [IP_ADDRESS], Blood Sample Collection  
Description of change:   Deleted capi[INVESTIGATOR_30981].  
Rationale for change:   To minimize laboratory sampling options.  
8. Section [IP_ADDRESS], Medical and Treatment History  
Description of change:   Added text for clarity on what w ould be defined as 
documentation needed for previous AD medication history.  Defined the collective 
meaning of  "inadequate response " for clarity of data collected . 
Rationale for change:   To address European regulatory requirements (for the intended 
target population/ indication ). 
Incyte Corporation  Page 111 of 111 
Protocol INCB [ZIP_CODE] -305 Am 6 Version 7 22 FEB 2023  
VV-CLIN -011993  CONFIDENTIAL  9. Appendices  
Description of change:   Revised the appendices as follows.  
  
 
• Moved original Appendix B (COVID -19 Pandemic Mitigati on Strategies a nd 
Instructions ) to Appendix C.  
• Moved original Appendix C (Body Surface Area Calculation Guides) to Appendix D.  
• Deleted original Appendix D (Centers for Disease Control And Prevention Growth 
Charts [for the US Region]) and Appendix E [United Kin gdom –World Health 
Organization Growth Charts [for the EU Region])  
• Changed  original Appendix F (Eczema Area and Severity Index) to Appendix E.  
   
 
 
10. Appendix C, COVID -19 Pandemic Mitigation Strategies and Instructions  
Description of change:    
Rationale for change:    
 
11. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  

Signature [CONTACT_11032]-CLIN-011993 v12.0
Signature [CONTACT_11032]-CLIN-011993 v12.0Approval Task
22-Feb-2023 21:32:24 GMT[PHONE_006]
Approval Task
22-Feb-2023 21:35:13 GMT[PHONE_006]
Approval Task
22-Feb-2023 22:17:59 GMT[PHONE_006]
Approval Task
Document Preparer
22-Feb-2023 22:53:22 GMT[PHONE_006]
Approval Task
23-Feb-2023 02:45:14 GMT[PHONE_006]
